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Obesity: epidemiology and classification 
 
Obesity is a metabolic disease, whose diffusion has been exponentially increased in the last 
thirty years1. In the light of this alarming data, the world health organization defined 
obesity as a global epidemic. Particularly relevant is the explosion of infantile obesity: 
recent data demonstrated that the number of obese children in France is dramatically 
increased in the last decade2, and the prevalence of over-weight children in USA has 
doubled in the last forty years3. The fast increase in obesity incidence is linked to an 
excessive food intake and to a sedentary life style, typical of western population. But, at 
individual level, can be exacerbate by genetic susceptibility. The weight gain is in fact the 
result of interaction among genetic, environmental and psychosocial signals that, 
integrated by physiological factors, regulate energy store and consumption4. Obesity is 
strictly related to deep changes in physiological functions, leading to an altered and 
ectopic distribution of adipose tissue. This can severely compromise cardiac and 
respiratory function, due to fat accumulation around heart and rib cage. Moreover the 
increase of intra-abdominal visceral fat deposition correlates to insulin-resistance, type 2 
diabetes, dyslipidemia and hypertension5. These comorbidities contribute to raise the 
mortality rate associated to the pathology that positively correlates to body weight gain6. 
Obesity is the result of an altered energy balance that results in excessive accumulation of 
adipose tissue. Clinical diagnosis of obesity is based on the Body Mass Index (BMI), 
calculated as the ratio between the body weight (kilograms) and the square of the height 
(meters). Based on the indication of the World Health Organization a BMI over 25 
correlates with overweight, while a value of BMI over 30 is considered indicative of 
obesity4.   
 
 
Insulin resistance: the evil partner of obesity 
 
Recent studies highlighted a strong correlation between obesity, insulin resistance, and 
type 2 diabetes7. In the early phase, this pathology is characterized by a reduced insulin 
sensitivity of skeletal muscle, adipose tissue and liver8. In the later state of disease the 
ability to secrete insulin by pancreatic beta cells is also impaired9. In physiological 
condition, insulin secreted from pancreatic beta cells in response to increased glucose 
plasma level, exerts multiple systemic effects by binding its receptor (insulin receptor, IR) 
in several organs. In skeletal muscle and adipose tissue the binding of insulin to IR 
activates the phosphorylation on tyrosine residues of insulin receptor substrate (IRS) that 
in turn phosphorylates and activates the phosphatidylinositide 3-kinase (PI3K). Through 
a cascade of intracellular signals, insulin induces the membrane traslocation of the insulin-
dependent glucose transporter Glut4 that allows the internalization of glucose in muscle 
and adipose cells10. In liver insulin stimulates the expression of genes involved in glucose 
metabolism and lipogenesis (glucokinase, pyruvate kinase, acetilCoA carboxylase, fatty 
acid synthase); concomitantly it inhibits transcription of gene encoding for 
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phosphoenolpyruvate carboxykinase (Pepck), key enzyme of gluconeogenesis11. In insulin 
resistance state the ability of skeletal muscle and adipose tissue to uptake circulating 
glucose is impaired because of reduced membrane translocation of Glut411. Moreover in 
obese subjects the high levels of circulating free fatty acids and other metabolites such as 
ceramides and diacilglycerols, activate different protein kinases, such as protein kinase C 
(PKC), Jun kinase (JNK) and the inhibitor of nuclear factor kB (IKB) that increase serine 
residues of IRS, preventing the tyrosine phosphorylation12. This prevent the activation of 
insulin signaling, contributing to the onset of insulin resistance13. In this context, free fatty 
acids represent a dangerous enemy of liver: by inhibiting IRS activation, they block 
insulin-mediated activation of Pepck, leading to a higher synthesis of hepatic glucose that 
can be released in plasma and worsens the hyperglycemia14. The reduced insulin hepatic 
clearance leads to increased levels of insulin in peripheral districts, inducing a further 
down-sensitization of insulin receptors. 
Hyperinsulinemia and insulin-resistance are also related to dyslipoproteinemia and 
contribute to alterations of plasma lipid profile typically associated to obesity: reduced 
high density lipoproteins (HDL), high levels of cholesterol and low density lipoprotein4. 
 
 
The adipose organ 
 
In mammals the adipose organ is traditionally composed by white adipose tissue (WAT) 
and brown adipose tissue (BAT). Two types of WAT have been described: subcutaneous 
and visceral. Subcutaneous WAT is located anteriorly in axillary region and posteriorly 
from dorsal-lumbar to inguinal region. Visceral WAT is instead located in the rib cage 
and in abdominal cavity and consists of retroperitoneal, peritoneal, mesenteric, epicardial 
and gonadic (referred to as epidydimal in males) WAT15. BAT has been localized by 
positrons emission tomography (PET) in the inter-scapular region, and it has been 
demonstrated that this fat depot is functional even in adult human subjects16. The main 
function of adipose tissue is to store lipids as triglycerides and to release them in response 
to energy demands. However several publications demonstrated that adipose tissue plays 
an important role in multiple physiological processes, such as immunity17 and 
thermogenesis18. Adipose tissue also has important mechanical properties, serving to 
protect delicate organs (the eye, for example, is surrounded by fat) and to cushion body 
parts exposed to high levels of mechanical stress19.  
 
Adipose tissue: white, brown and beige 
White and brown adipocytes are different in term of morphology and function. The 
classical view of the function of WAT is the storage of lipids in form of trygliceride, so in 
the past it has been considered just a long-term fuel reserve, which can be mobilized 
during food deprivation with the release of fatty acids for oxidation in other organs. Thus, 
the size of the adipose tissue stores increases in periods of positive energy balance and 
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declines when energy expenditure is in excess of intake20. Nowadays it has been 
established that adipose tissue is not only a storage center for lipids but a master regulator 
of energy balance and nutritional homeostasis21, that plays a key role in metabolic 
regulation. Moreover adipose tissue is now known to express and secrete a variety of 
bioactive peptides, known as adipokines, which act at both the local (autocrine/paracrine) 
and systemic (endocrine) level22. Adipose tissue, in fact, produces cytokines and cytokine-
related protein (Leptin23, TNF24, IL-625, adiponectin25, resistin26), proteins involved in the 
fibrinolytic system (PAI-127), lipids and proteins for lipid metabolism or transport 
(lipoprotein lipase, apolipiprotein E, non esterified fatty acids), and enzymes involved in 
steroid metabolism28. In addition to these efferent signals, adipose tissue expresses 
numerous receptors that allow it to respond to afferent hormonal and nervous signals. 
Thus, besides the biological repertoire necessary for storing and releasing energy, adipose 
tissue contains the metabolic machinery to permit communication with distant organs 
including the central nervous system22.  
White adipose tissue is mostly composed of unilocular high dimensional (70-80 µm) cells 
with peripheral nucleus and a large cytoplasmic lipid vacuole that occupies 90% of cellular 
volume, where triglycerides are stored. This vacuole is separated from the rest of the 
cytoplasm by an electron-dense barrier, which contains important structural proteins such 
as perilipin29. During weight gain, different fat depots enlarge via hyperplasia (increase in 
the number of adipocytes), by hypertrophy (increase of adipocyte size) or both30. Different 
WAT depots showed relevant differences in terms of function and morphology. Visceral 
adipocytes have long been known to be smaller than their subcutaneous counterparts both 
in lean and in obese animals31. This is relevant especially in pathological condition such as 
obesity that is related to a global inflammatory status. It has been proposed that obesity-
related inflammation is the result of macrophage infiltration in WAT32. Several studies 
suggest that adipose tissue inflammation is attributable in large part to the pro-
inflammatory actions of bone marrow-derived white adipose tissue (WAT) macrophages. 
These studies demonstrate that macrophage numbers and/or gene expression of 
macrophage inflammatory markers in WAT are positively correlated with adipocyte size 
and body mass index (BMI) in mice33 and negatively correlated with weight loss in obese 
humans34. Macrophages are the predominant source of tumor necrosis factor-α (TNF-α) 
and a significant source of interleukin-6 (IL-6) and nitric oxide in WAT of obese (ob/ob, 
db/db) mice and humans35. These molecules affect cellular metabolism: TNF, for example, 
reduces insulin sensitivity and increases lipolysis in adipocytes, inhibiting in this way 
adipogenesis36. It in fact represses the master regulator of adipocyte differentiation, 
Peroxisome Proliferator-Activated Receptor γ (PPARγ) at transcriptional, translational 
and post-translational level37. Moreover increase in macrophage inflammatory gene 
expression in WAT immediately precedes or is coincident with the onset of 
hyperinsulinemia in murine diet-induced obesity38, and obese mice with genetically 
ablated macrophage inflammatory (i.e., nuclear factor κB) signaling are protected from 
insulin resistance39. Together, these observations implicate macrophage activation in the 
development of obesity-associated WAT inflammation and insulin resistance. Saverio 
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Cinti and collaborators demonstrated that adipose tissue infiltrated macrophages (ATMs) 
surround dead adipocytes, whose number increases in obese state, and form a typical 
“crown-like structure” (CLS) that scavenges residual adipocyte lipids40. Cinti and 
colleagues also demonstrated that visceral depots are the prevalent sites of adipocyte death 
and macrophage infiltration. Their data suggest that the higher incidence of metabolic 
disorders associated with visceral fat accumulation could be due to a greater susceptibility 
to death of the adipocytes. The conclusion they reach is that visceral adipocytes reach the 
critical size triggering death before subcutaneous adipocytes41. Thus the established 
concept that larger adipocytes (such as subcutaneous adipocytes) correlate with greater 
insulin resistance42 should be reconsidered in its pathogenic mechanism: it appears more 
appropriate to refer to positive correlation between inflammation (related to insulin 
resistance) and the critical size that adipocytes can reach before they collapse. A recent 
paper supports a preferential visceral versus subcutaneous macrophage infiltration also in 
obese human patients43. Some authors have hypothesized that the differences in size, 
function, and potential contribution to disease shown by the different fat depots may be 
due to regional intrinsic differences, including differences in preadipocyte 
characteristics44,45. Accordingly to this hypothesis, the greater propensity of visceral 
compared with subcutaneous adipocytes to die could be explained by intrinsic cellular 
differences among different fat depots. Regarding adipose tissue and macrophages it is 
important to underline the role of a population of resident macrophages, typical of 
functional adipose tissue: M2 macrophages (or ‘‘alternatively activated’’)46. These 
macrophages differ from the classic M1 macrophages, typically associated to a pro-
inflammatory phenotype47. They play a role in tissue remodeling and wound healing and 
respond to IL-4 and IL-13 by secreting anti-inflammatory cytokines like IL-10 and IL-1 
receptor antagonist48. In lean animals, M2 macrophages dominate the adipose tissue 
resident population. As obesity progresses, however, more M1 macrophages infiltrate the 
fat pad, causing insulin resistance49. Adipose M2 macrophage number does not diminish 
in obesity and, in fact, may increase; but there is a major shift in the M1/M2 ratio 
favoring a pro-inflammatory state48 (Figure 1).  
 
  
Figure 1: Adipose tissue hypertrophy consequent to obese state increases M1 macrophages 
recruitment. They surround dead adipocyte, form typical “crown-like structures” (CLS) that 
scavenge residual adipocyte lipid. Adapted from Rosen and Spiegelman, 201421 
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In the recent years the fundamental role of another type of fat, brown adipose tissue, has 
been deeply investigated. The unequivocal discovery of brown fat in adult human 
subjects50 opened a new way for studying whether metabolic potential of this fat depot can 
be exploited to treat metabolic disorders. Brown adipocytes are highly specialized cells 
that dissipate stored chemical energy in the form of heat. They do this through the 
actions of uncoupling protein-1 (UCP-1), a brown adipose tissue (BAT)-specific protein 
located within the mitochondria, which are densely packed in these cells. UCP-1 catalyzes 
a proton leak across the inner mitochondrial membrane, thus ‘‘uncoupling’’ fuel oxidation 
from ATP synthesis51. The function of BAT is to transfer energy from food into heat; in 
fact it regulates body temperature via non-shivering thermogenesis. Heat production and 
thermogenic capacity are under the control of norepinephrine released from sympathetic 
nerves. Heat production from brown adipose tissue is activated whenever the organism is 
in need of extra heat, e.g., postnatally, during entry into a febrile state, and during arousal 
from hibernation, and the rate of thermogenesis is centrally controlled via a pathway 
initiated in the hypothalamus18. Sympathetic nervous system (SNS) plays a key role in the 
activation of thermogenic program: several hypothalamic and extrahypothalamic areas act 
as integrators of the cold response52. The cold thermal afferent circuit from cutaneous 
thermal receptors, through thermosensory neurons in the dorsal horn of the spinal cord, 
ascends to activate neurons in the lateral parabrachial nucleus. These neurons drive 
GABAergic interneurons in the preoptic area (POA) to inhibit warm-sensitive, inhibitory 
output neurons of the POA. The resulting disinhibition of BAT thermogenesis-
promoting neurons in the dorsomedial hypothalamus activates BAT sympathetic 
premotor neurons in the rostral ventromedial medulla, including the rostral raphe 
pallidus, which provide excitatory, and possibly disinhibitory, inputs to spinal sympathetic 
circuits to drive BAT thermogenesis53. The result of the activation of this intricate neural 
circuitry is the secretion of cathecolamines at the level of BAT: norepinephrine activates 
adrenergic receptors on adipocytes, which triggers a signal transduction cascade that leads 
to adaptive switch in the expression of thermogenic genes54. Sympathetic neurons release 
catecholamines, which bind to β3-adrenergic receptor, leading to activation of adenylyl 
cyclase (AC), increased cyclic AMP (cAMP) concentrations and enhanced PKA 
activity18. Recently it has been reported that also increased concentrations of natriuretic 
peptides trigger BAT thermogenesis through activation of cyclic GMP-dependent 
protein kinase (PKG)55: natriuretic peptides bind natriuretic peptide receptor A (Npra), 
which activates guanylyl cyclase (GC) to increase the concentrations of cyclic GMP 
leading to activation of PKG55. Activated PKA and PKG drive transcriptional responses 
in brown adipocytes through the activity of phosphorylated Creb and p38 Mapk56. p38 
Mapk phosphorylates and activates the activating transcription factor 2 (Atf2) and the 
master regulator of mitochondrial biogenesis Pparγ coactivator 1α, Pgc-1α57, which 
induce the transcription of downstream thermogenic genes, including Ucp158. Pgc-1α 
binds DNA through interactions with Pparγ59, Pparα, retinoid X receptors (Rxrs) and 
thyroid receptor (TFx)60. Additionally, catecholamines increase the amounts of miR-196a, 
resulting in increased C/ebpβ expression, which helps drive the thermogenic gene 
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program61. Importantly, activation of PKA and PKG also acutely induces lipolysis. Free 
fatty acids released from lipid droplets are oxidized by mitochondria to produce heat. 
Proton leak through Ucp1 is activated by long-chain fatty acids released from the 
mitochondrial membrane by phospholipase 2 (Pla2)62.  
In addition to nerve terminals, alternatively activated macrophages (M2) in BAT produce 
catecholamines in response to cold that further tighten up the thermogenic activation63. 
 
 
 
Figure 2:  Induction of thermogenesis: cathecolamines and natriuretic peptide binding to brown 
adipocyte surface activate a molecular cascade leading to Ucp1 activation. From Harms and Seale, 
201354 
 
Moreover the SNS distributes signals to white or brown adipose depots according to 
energy demand, thus both the effect of food deprivation and the effect of cold exposure 
determine SNS input to adipose tissue64. 
Human newborns have significant brown fat depots, presumably to provide heat in the 
cold environment encountered at birth. Adult humans, however, were felt to be largely 
devoid of brown fat unless specifically challenged by chronic cold65 or by states of 
catecholaminergic excess66. The existence of significant depots of brown fat in adult 
humans was proven based upon radiological observations of symmetrical [18F]-2-fluoro-
D-2-deoxy-Dglucose (FDG) positron emission tomography (PET)-positive loci in the 
supraclavicular and spinal regions of patients getting such scans for cancer diagnosis or 
staging. Biopsies confirmed the presence in these regions of UCP-1+ adipocytes, 
consistent with brown fat50,67,68. In rodents, prolonged cold exposure or adrenergic 
signaling can provoke the appearance of clusters of UCP-1+ cells with a brown fat-like 
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morphology within white fat depots. Their abundance varies dramatically between depots, 
with the highest numbers found in inguinal and retroperitoneal fat. These inducible cells 
have been called ‘‘beige’’ or ‘‘brite’’ adipocytes and share an overlapping but distinct gene 
expression pattern compared to classic brown adipocytes21. Both express a core program of 
thermogenic and mitochondrial genes, including Ucp1. However, murine beige cells also 
express the surface markers such as Cd137 and Tmem26 that are not expressed in brown 
adipocytes69. Other genes, like Zic1, appear to mark classic brown adipocytes, but not 
beige cells70. Classical brown fat cells have a higher basal UCP1 expression and elevated 
uncoupled respiration (relative to white or beige cells) before hormonal stimulation. Beige 
cells have low basal UCP1 expression and uncoupled respiration, comparable to white 
cells. However, stimulation with a β-adrenergic agonist elevates UCP1 to levels seen in 
brown fat cells. This suggests that beige cells are uniquely programmed to be bifunctional 
suited for energy storage in the absence of thermogenic stimuli but fully capable of 
turning on heat production when they receive appropriate signals69. Moreover selective 
loss of classic brown fat (for example by ablation of the type IA BMP receptor) causes 
compensatory induction of beige fat, restoring both body temperature and resistance to 
diet-induced obesity71. The thermogenic profile of beige adipocytes is reversible: beige 
adipocytes acquired in WAT during cold exposure lose Ucp1 expression and are retained 
after mice are moved back to warmer conditions.  When these mice are re-exposed to 
cold, the same cells again induce Ucp1 expression72. Beige adipocytes are most abundant 
in the inguinal WAT, the major subcutaneous depot in rodents73. However, Ucp1-
expressing adipocytes are evident in most WAT depots in response to cold exposure74,75. 
Petrovic and colleagues found that a subset of adipocytes isolated from epidydimal WAT 
(a visceral fat depot) differentiated in vitro from the stromal vascular fraction (an enriched 
source of preadipocytes) of WAT express Ucp1 in response to chronic treatment with 
Pparγ activators, highlighting the role played by Pparγ	   in the establishment of browning 
of visceral adipocytes76. There is evidence from animal models that enhancement of the 
function of brown adipocytes, beige adipocytes or both in humans could be very effective 
for treating type 2 diabetes and obesity77. In recent years several pathways and factors that 
can induce browning of white fat have been identified and potentially they represent new 
targets in the therapy of metabolic disorders. Spiegelman and collaborators, starting from 
the observation that increasing the amounts of Pgc-1α in muscle protects sedentary mice 
from obesity78, found that WAT of Pgc-1α transgenic mice contained more beige 
adipocytes than that of wild-type mice79. In a search for effectors of the enhanced energy 
expenditure in these mice, they identified Fndc5 (encoding fibronectin type III domain 
containing 5) as a Pgc-1α target gene and showed that its product was secreted from 
myocytes in the form of a previously undiscovered hormone, which they called irisin: irisin 
stimulates the browning of WAT through specific actions on the beige preadipocyte 
population79. Hepatic bile acids and FGF21 have also been shown to enhance browning, 
as have cardiac hormones like atrial and ventricular natriuretic peptides (ANP and BNP) 
and cardiotrophin-180. These agents act through their respective receptors to induce 
browning by various overlapping mechanisms. Bile acids, for example, activate the TGR5 
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receptor, which in turn induces the deiodinase enzyme that promotes intracellular T3 
formation81. Thyroid hormone and catecholamines both induce the local formation of 
BMP8b, which sensitizes the brown adipocyte to further adrenergic signaling. BMP8b 
also acts in the brain to direct SNS signaling specifically to BAT82 (Figure 3).  
 
Figure 3: Secreted factors that recruit brown adipocytes, beige adipocytes or both. From Harms 
and Seale, 2013 54 
From precursors to differentiated adipocytes 
Adipocytes develop from preadipocytes, which themselves derive from precursor cells. 
The so-called stromal vascular fraction (SVF) is separated from mature adipocytes by 
collagenase digestion and low-speed centrifugation. When the SVF is cultured ex vivo, 
blood cells, endothelial cells, and other non-fibroblastic cells do not attach to the dish83. 
What remains can be almost completely differentiated using a hormonal cocktail that 
typically includes insulin, glucocorticoids, phosphodiesterase inhibitors, and often a Pparγ 
agonist83. This does not allow, however, for identification of the specific cell type within 
the SVF that populates the mature adipocyte fraction in vivo, and this has spurred a 
number of studies involving selective flow sorting using antibodies against various cell 
surface markers21. Most of these studies have shown that mesenchymal and stem cell 
markers such as CD34 and Sca-1 strongly enrich for adipogenic precursors84. More 
recently, other cell surface markers typical of subpopulation of stromal cells that 
differentiates into adipocytes have been identified, such as PDGFRα85. Interestingly 
several studies in the last decade demonstrated that brown and white adipocytes do not 
develop from common precursors, as previously thought. Data obtained over the last few 
years have shown that muscle and classical brown fat derive from the same or very similar 
precursors86. The transcriptional cofactor PRD1-BF-1-RIZ1 homologous domain-
containing protein-16 (PRDM16) has been in fact identified as a dominant regulator of 
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the brown fat program87: knock down of PRDM16 in primary brown fat cultures induces 
a phenotypic switch to skeletal muscle, while expression of PRDM16 in myoblasts 
commits them to brown fat88. Moreover lineage-tracing studies using the muscle-selective 
Myf5-Cre showed that skeletal muscle and classical brown fat share a common 
precursor88. These findings helped to explain why brown preadipocytes express some 
myogenic genes not seen in white preadipocytes89.  
Beige adipocytes do not derive from the same Pax7+Myf5+ precursor cells that give rise to 
classic interscapular BAT88. In order to explain the origin of beige adipocytes the first 
theory proposed was that these cells derive from transdifferentiation of existing mature 
white adipocytes. More recently, however, unique precursor cells within the white fat pad 
have been identified using sorting and/or cloning by limiting dilution90,91. A lineage 
tracing study reported that cold exposure-induced “browning” of white fat required de 
novo adipogenesis92. Another study demonstrated that beige adipocytes appearing in 
response to an initial period of cold exposure, showed morphology and gene expression 
pattern similar to that of a typical white adipocyte after reintroduction to warm 
conditions72. After new exposure to the cold, many of these cells induce again the 
thermogenic program, suggesting that precursor cell differentiates into a beige adipocyte 
when conditions require it to do so, and converts back to an energy-storing ‘‘white’’	  
adipocyte when heat generation is no longer a priority. Collectively, these studies 
demonstrate that certain adipose populations show extraordinary plasticity when 
physiological conditions change.	  
At the cellular level, adipogenesis occurs in two phases: determination and terminal 
differentiation. During determination, possible alternate fates of an adipose precursor cell 
become progressively restricted such that it becomes ‘‘committed’’ to the adipose lineage 
and becomes a preadipocyte. Terminal differentiation, on the other hand, is the process 
by which the preadipocyte acquires the characteristics of mature adipocytes21. Most of the 
cellular models that have been employed to study adipogenesis are already committed to 
the adipose lineage (e.g., 3T3-L1, 3T3-F442A): for this reason we know much more 
about the process of terminal differentiation93. Nowadays other immortalized cell cultures 
are available, such as C3H10T1/2, an adipogenic cell line that has been isolated from 
bone marrow and that conserves features of early not-committed precursor. Thus this cell 
line is particularly useful for in-depth investigations on molecular mechanism occurring at 
the beginning of the adipocyte differentiation program. Some pre-adipocyte models (for 
example, the mouse cell lines 3T3-L1, 3T3-F442A) undergo one or two rounds of cell 
division prior to differentiation, whereas others (C3H10T1/2 and human pre-adipocytes) 
differentiate without post-confluence mitosis94. In order to investigate signaling pathways 
that regulate the adipogenic/nonadipogenic fate of multipotent cells, several studies have 
been performed using bone marrow-derived mesenchymal cells. For this reason the 
‘‘bone-fat switch’’ is the most commonly described fate choice. It has been demonstrated 
that the Wnt and hedgehog pathways promote osteogenesis and inhibit adipogenesis in 
both committed and uncommitted precursor cells93. Even though these pathways utilize 
different signaling intermediates, both have been reported to converge on the 
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transcription factor COUP-TFII, which inhibits proadipogenic transcription factors like 
PPARγ and C/EBPα95,96. Conversely, insulin growth factor (IGF) and insulin signaling is 
strongly proadipogenic97. There are many other players that influence adipogenic 
program, and some of them exerts their action on specifics ligand, cell type, stage of 
differentiation, or other experimental conditions21. The transforming growth factor β	  and 
bone morphogenic protein (TGFβ/BMP) is a superfamily of proteins that participate in 
the regulation of adipocyte differentiation. TGFβ and its downstream effector Smad3 
have been shown to exert both pro- and anti-adipogenic actions in different in vitro and 
ex vivo models98,99. Among the BMPs, BMP2 and BMP4 increase both osteogenesis and 
adipogenesis, depending upon other components of the differentiation cocktail, whereas 
BMP7 promotes brown adipogenesis specifically100. Also other members of the 
superfamily, like the activins, have disparate effects on adipogenesis and adiposity101. 
Similarly, the fibroblast growth factor (FGF) and Notch-signaling pathways have been 
reported to have complex effects on adipogenesis: Notch signalling seems to be required 
for 3T3-L1 differentiation as suppression of Notch expression or activity blocks 
differentiation in these cells102. Moreover, in 3T3-L1 cells, loss of HES1, a bHLH 
transcription factor that mediates some of the effects of Notch, impairs adipogenesis and 
induces expression of a known inhibitor of differentiation, DLK1/PREF1103. However, 
adipocyte differentiation in vitro is also blocked when Notch signalling is activated by 
Jagged or by constitutively active HES193.  
The ‘‘master regulator’’ of fat cell formation is PPARγ, as it is both necessary and 
sufficient for adipogenesis; PPARγ is so potent as adipogenic factor that it can drive 
nonadipogenic cells like fibroblasts and myoblasts to become adipocytes104,105. It has been 
reported that humans with rare loss-of-function mutations in PPARγ have lipodystrophy 
and severe insulin resistance, confirming the crucial role of this nuclear receptor in 
adipogenesis, as suggested by murine studies. The bZIP factors CCAAT-enhancer-
binding proteins C/EBPα, C/EBPβ, and C/EBPδ are also important inducers of 
adipogenesis, with C/EBPβ and C/EBPδ acting early in terminal differentiation (Figure 
4). Differentiation is promoted by a positive feedback loop between PPARγ and 
C/EBPα106,107; then a second positive feedback loop between PPARγ and C/EBPβ 
reinforces the decision to differentiate108. Many of these factors bind at common genomic 
‘‘hot spots,’’ with early factors establishing chromatin accessibility at the same locations 
that will later be bound by downstream factors109. Recently, many other transcription 
factors have been identified that promote or inhibit adipogenesis; most of these induce or 
repress PPARγ expression110. PPARγ, in turn, directly binds to and regulates a huge 
number of genes that control all aspects of adipocyte metabolism21. There has been recent 
progress in identifying transcription factors involved in adipose determination: an 
expression screen in embryonic fibroblasts with and without adipogenic potential 
identified zinc-finger protein Zfp423 as a transcriptional determinant of the adipose 
lineage111. Zfp423 amplifies the effects of BMPs via a SMAD interaction domain 
inducing adipose lineage commitment. Zfp423 expression in the developing adipocyte is 
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repressed by the highly related factor Zfp521, which promotes osteogenesis and inhibits 
adipogenesis through interactions with Ebf1, a transcription factor required for early 
adipose commitment112,113. Another player in the regulation of adipogenic lineage 
commitment is Tcf7l1, although it acts in a very different manner by responding to 
confluency and mediating changes in structural proteins that regulate differentiation114. 
The elements of the adipogenic transcriptional cascade are common for most adipose 
depots, but they differ in some details. For example, mice lacking C/EBPα are generally 
lipodystrophic but still have mammary fat and brown adipose tissue115.  
 
 
Figure 4: Signals from activators and repressors of adipogenesis are integrated in the nucleus by 
transcription factors that directly or indirectly regulate expression of peroxisome proliferator-
activated receptor γ (PPARγ) and CCAAT-enhancer-binding protein α (C/EBPα). From Rosen 
and MacDougald, 200693 
 
Regarding brown adipose tissue, Ebf2 seems to be particularly important for development 
of this fat depot, as it recruits PPARγ to unique sites that determine brown adipocyte 
identity116.  Interestingly, much of the specialized function of brown adipocytes is 
controlled by transcriptional cofactors, which do not bind DNA directly but they 
determine which targets are bound and activated by transcription factors. The most 
important of these is PGC-1α, a dominant regulator of mitochondrial biogenesis, 
oxidative metabolism, and thermogenesis in brown fat117. PGC-1α exerts its actions on 
mitochondria and oxidation via interactions with transcription factors like ERRα118, Nrf-
2, PPARα, and PPARγ119. Transcription factor partners of PGC-1α that control 
thermogenesis are still unknown; in fact ablation of PGC-1α	   reduces the expression of 
many thermogenic genes, but do not affect the expression of another set of brown fat-
selective genes. The necessity to determine other key player in brown fat identity, led to 
the identification of PRDM1687. PRDM16 binds C/EBPβ (and presumably other 
transcription factors) and recruits the corepressor proteins C-terminal-binding protein 1 
and 2, CtBP1 and CtBP2, to prevent gene expression associated with either white fat or 
muscle120,121. Another interesting cofactor is transducin-like enhancer protein 3 (TLE3) 
because it competes with PRDM16 for PPARγ binding, blocking thermogenesis in favor 
	   Introduction	  
13	  
of genes more indicative of white adipose tissue. Overexpression of TLE3 in fat impairs 
brown fat function, while adipose-specific knockouts have the opposite phenotype122. 
The role of noncoding RNAs in adipose differentiation has emerged from recent studies. 
MicroRNA (miRNA) in particular have been studied in this regard and at least 20 
miRNA species have now been shown to affect adipogenesis, though some are not 
specific for fat and appear to be required for mesenchymal cell differentiation in general123. 
Some miRNAs affect directly adipogenic transcription factors like PPARγ and C/EBPα, 
whereas others regulate important signaling pathways like insulin-Akt, TGFβ, and 
Wnt124. Other miRNAs have a preferential effect on brown and/or beige adipocyte 
formation and function, including some that target PRDM16 and C/EBPβ125. 
Oxidative potential of adipose tissues: a mitochondrial issue 
The oxidative capacity of organs and tissues is related to their content in mitochondria, 
the organelles generating the majority of cellular ATP via oxidative phosphorylation 
(OXPHOS). The role of mitochondria in adipose tissue is most apparent in brown 
adipose tissue, where flux through the electron transport chain (ETC) generates heat in 
the process of thermogenesis, a potentially important mechanism regulating systemic 
metabolism even in adult humans126-129. In brown fat, electron transport is greatly 
accelerated due to tissue-specific expression of the mitochondrial UCP1. UCP1 partly 
dissipates the proton gradient reducing but not completely abolishing the synthetic 
activity of the mitochondrial ATPase127,130-132, thus driving continuous accelerated electron 
transport to meet ATP demands. UCP1-mediated uncoupling alone, however, can not 
fully account for the large thermogenic capacity of brown adipocytes in the absence of 
mechanisms that ensure continuous substrate delivery to the ETC. Thus, brown 
adipocyte mitochondria also contain high levels of CPT1b, which is critical for the entry 
of fatty acids into the mitochondria. β-Oxidation, in turn, generates large amounts of 
reducing equivalents for the ETC. 
In contrast, white adipocytes have been described to contain less mitochondria compared 
with brown adipocytes or muscle. However, mitochondrial density increases dramatically, 
and mitochondrial remodeling occurs during white adipocyte differentiation133-135, 
suggesting that mitochondrial functions are required to support the multiple biological 
roles of mature white adipocytes. Interestingly, a recent compendium of mitochondrial 
proteins from 14 different mouse tissues indicates that white adipocyte mitochondria 
contain a more diverse protein repertoire than mitochondria from heart, skeletal muscle, 
or brain136. Thus, white adipocyte mitochondria appear to be equipped for a broader array 
of functions compared with mitochondria in tissues that must sustain rapid bursts of 
energy-requiring processes. Among the mitochondrial functions that may be relevant for 
white adipose tissue function are the anaplerotic generation of metabolic intermediates for 
fatty acid synthesis and esterification137, the maintenance of a robust pathway for the 
folding and secretion of high abundance circulating proteins such as adiponectin138, and 
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interactions between mitochondrial function and components of the insulin signaling 
pathway138. 
 
Other contributors to energy metabolism 
Skeletal muscle 
Skeletal muscle is a high-energy demand tissue, rich in mitochondria that sustain the high 
oxidative request imposed on this tissue by contraction. Mitochondria play a critical role 
in providing sufficient levels of ATP needed; this high-level requirement for ATP by 
sarcomeres has likely contributed to the distinct subsarcolemmal and sarcomere-associated 
populations of mitochondria in muscle. Moreover, muscle cells must maintain metabolic 
flexibility, defined as the ability to rapidly modulate substrate oxidation as a function of 
ambient hormonal and energetic conditions. For example, healthy muscle tissue 
predominantly oxidizes lipid in the fasting state, as evidenced by low respiratory quotient 
(RQ), with subsequent transition to carbohydrate oxidation (increased RQ) during the fed 
state. Availability of fuels, particularly lipids, and capacity to oxidize them in the 
mitochondria are also critical for sustained exercise. Thus, mitochondrial functional 
capacity is likely to directly affect muscle metabolic function and, because of its large 
contribution to total body mass, to have a significant impact on whole-body metabolism. 
Skeletal muscle is the largest insulin-sensitive organ in humans, accounting for more than 
80% of insulin-stimulated glucose disposal. Thus, insulin resistance in this tissue has a 
major impact on whole-body glucose homeostasis. Indeed, multiple metabolic defects 
have been observed in muscle from insulin-resistant but normoglycemic subjects at high 
risk for diabetes development, including reduced insulin-stimulated glycogen synthesis139-
141, alterations in insulin signal transduction142; and increased muscle lipid accumulation143. 
Although it remains unclear whether any of these defects plays a causal role in insulin 
resistance, intramuscular lipid excess strongly correlates with the severity of insulin 
resistance, even after correction for the degree of obesity143, and has been observed in 
muscles of multiple fiber types144. Moreover, lipid excess has been linked experimentally to 
induction of insulin resistance145 and alterations in insulin signal transduction146-148. 
Thus, one possible mechanism by which impaired mitochondrial function might 
contribute to insulin resistance is through altered metabolism of fatty acids. Increased 
tissue lipid load, as observed in obesity, and/or sustained inactivity, may lead to the 
accumulation of fatty acyl coenzyme A (CoA), diacylglycerols, ceramides, products of 
incomplete oxidation, and ROS, all of which have been linked experimentally to reduced 
insulin signaling and action145-151. Additional mechanisms potentially linking impaired 
mitochondrial oxidative function to insulin resistance include reduced ATP synthesis for 
energy-requiring functions such as insulin-stimulated glucose uptake, abnormalities in 
calcium homeostasis (necessary for exercise-induced glucose uptake)152-154 and reduced 
ATP production during exercise155, potentially contributing to reduced aerobic capacity, 
muscle weakness, and decreased voluntary exercise. 
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Liver 
The liver plays a central, unique role in carbohydrate, protein, and fat metabolism. It is 
critical for maintaining glucose homeostasis during fuel availability, via storage of glucose 
as glycogen or conversion to lipid for export and storage in adipose tissue, and in the 
fasting state, via catabolism of glycogen, synthesis of glucose and ketogenesis. In turn, 
these responses are regulated by the key hormones, insulin and glucagon, which modulate 
signaling pathways and gene expression, leading to inhibition or stimulation of glucose 
production, respectively. 
Recent studies in humans have highlighted the importance of disordered hepatic 
metabolism, including inappropriately increased hepatic glucose production, 
hyperlipidemia, and lipid accumulation, in both obesity and type 2 DM156. Similarly, data 
generated in rodent models also support an important role for the liver in diabetes 
pathogenesis. Liver-specific insulin receptor knockout (LIRKO) mice develop insulin 
resistance, glucose intolerance, impaired insulin suppression of hepatic glucose 
production, and altered patterns of hepatic gene expression157. Interestingly, these mice 
are also dyslipidemic and susceptible to atherosclerosis158. Given the diverse array of 
unique metabolic functions centered in the liver, it is not surprising that ultrastructure and 
function of hepatic mitochondria are distinct from that of muscle. Electron microscopy 
demonstrates that mitochondrial area is 44% lower in liver than in heart159, with smaller 
size, fewer cristae, and lower matrix density. Protein expression of multiple OXPHOS 
components and Tfam and citrate synthase activity are also lower in liver (i.e., 7% that of 
cardiac muscle)160. Despite lower OXPHOS capacity, state 3 respiration and respiratory 
control ratio are equivalent in liver and muscle. By contrast, the content of mtDNA is 
actually higher in the liver than in other tissues. Impairments in mitochondrial number 
and/or oxidative function could potentially affect multiple cellular functions within 
hepatocytes, both directly (e.g., reduced ATP generation, alterations in oxidative stress, 
reduced capacity for fatty acid oxidation) and indirectly, via effects on energy-requiring 
processes, including gluconeogenesis, synthesis of urea, bile acids, cholesterol, proteins 
and detoxification.  
Hepatic lipid accumulation may result when adipose lipid storage capacity is exceeded, as 
in obesity or adipocyte dysfunction (e.g., lipodystrophy)161. Alternatively, lipid 
accumulation may reflect an additional imbalance between de novo hepatic lipogenesis and 
mitochondrial oxidative metabolism. Interestingly, hepatic lipid accumulation is also a 
robust predictor of, not only hepatic, but also muscle and adipose insulin sensitivity162,163. 
Conversely, modest weight loss (about 8 kg) normalizes intrahepatic lipids in subjects 
with type 2 DM, in parallel with normalization of hepatic insulin sensitivity, even in the 
absence of changes in intramyocellular lipid accumulation or circulating adipocytokines164. 
Although these data highlight an intimate relationship between obesity, intrahepatic lipid 
metabolism, and insulin sensitivity in humans, mechanisms responsible for these links 
remain unclear. One possibility is that excessive hepatic lipid accumulation may play a 
central, pathogenic role in insulin resistance. This hypothesis comes from experimental 
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lipid loading, which can induce hepatic insulin resistance. Transgenic mice expressing 
lipoprotein lipase in the liver have a 2-fold increase in hepatic triglyceride content and are 
insulin resistant165. A second possibility is that hepatic insulin resistance itself contributes 
to alterations in mitochondrial oxidative capacity. Indeed, a recent paper demonstrated 
that mice with hepatic insulin resistance due to deletions of the major insulin receptor 
substrates (IRS-1 and IRS-2) have impaired mitochondrial function and biogenesis, as 
demonstrated by reduced NADH oxidation, reduced ATP production rates, reduced 
numbers of mitochondria per cell, reduced fatty acid oxidation, and increased hepatic 
triglyceride accumulation166. Mitochondrial dysfunction was reversed by deletion of 
Foxo1. These data indicate that normal insulin signaling, which inhibits Foxo1, is 
required for maintenance of normal mitochondrial function in this model. Finally, these 
data indicate that hepatic lipid accumulation and insulin resistance are intimately linked 
with mitochondrial oxidative dysfunction. 
 
 
Epigenetics 
 
In recent years the scientific community has witnessed a growing interest in epigenetics, 
as demonstrate by the increasing number of publications on this topic. Epigenetic 
modifications play a role in many DNA-related processes including transcription, 
recombination, DNA repair and replication167. Epigenetic modifications also regulate 
several important physiological and pathological processes such as embryonic 
development168, aging169 and cancer170. However nowadays, the importance of epigenetics 
has been recognized in many other fields relevant to human health, such as 
inflammation171, obesity172, insulin resistance, type 2 diabetes mellitus173, cardiovascular174, 
neurodegenerativ175 and autoimmune diseases176. Epigenetics can be defined as a set of 
processes and mechanisms that regulate gene activity, by modifying chromatin structure 
without changes in DNA sequence. Nucleosomes, the typical structure formed by 
histones in which the genomic DNA is folded in eukaryotic cells, are building blocks of 
the dynamic structure called chromatin177. During activation of gene transcription, 
chromatin adopts a locally accessible and transcriptionally active form referred to as 
euchromatin, while highly condensed and transcriptionally less active genetic material is 
known as heterochromatin178. The main epigenetic modifications include DNA 
methylation and histone modifications179. Amino acid residues on the histone tails are 
modified by post-translational acetylation, methylation, ADP-ribosylation and 
phosphorylation leading to significant changes in the chemical structure of the histone 
protein tails: acetylation of lysine residues of histone tails carried out by histone 
acetyltransferases (HATs) increases the distance between DNA and histones and the 
accessibility of transcription factors to gene promoter regions, while deacetylation by 
histone deacetylases (HDACs) induces chromatin packaging and reduces the accessibility 
of transcription factors to local chromatin regions180 (Figure 5).  
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Figure 5: Epigenetic regulators control chromatin remodeling, a) Histone acetylation and 
methylation at specific lysine or arginine residues (H3K4, H3K79, H3K36 and H4R3) opens 
chromatin and activates gene transcription, b) Histone methylation at H4K20, H3K9 and 
H3K27 silences gene transcription.  
  
 
Histone deacetylases 
 
Mammalian HDACs are listed into four classes based on their homology with yeast 
HDACs (Figure 6)181. Class I HDACs are ubiquitously expressed and are mainly 
localized in the nuclear compartment where they exert the most relevant histone 
deacetylase activity. Class II HDACs localize in the cytoplasm, shuttling into the nucleus 
in response to specific cellular signals. Class IIa HDACs are characterized by post-
translational regulation such as phosphorylation that determines their cytosolic 
localization, whereas dephosphorylation of Class IIa HDACs enables their translocation 
to the nucleus182-185. Class IIa HDACs feature only minimal histone deacetylase activity 
due to a swap of a key tyrosine residue in the catalytic domain with a histidine186; 
nonetheless, they act as scaffold molecules to recruit class I HDACs. Class IIb HDACs 
are localized in the cytoplasm and act mainly on non-histone substrates such as 
cytoskeletal and transmembrane proteins181. Class III HDACs, also known as sirtuins, are 
sensitive to changes in the intracellular NAD+/NADH ratio and they rely upon NAD+ 
hydrolysis for their deacetylase activity. In mammals, sirtuins regulate several functions, 
ranging from the control of cellular stress to energy metabolism187. Rodgers and 
collaborators188 investigated the molecular mechanisms responsible for the adaptive 
metabolic response to fasting and found that SIRT1 is involved in the metabolic control 
in mammals. These authors showed that in the fasted state, SIRT1 is induced in the liver 
and deacetylates PPARγ coactivator 1α (PGC-1α) at specific lysine residues in a NAD+- 
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dependent manner: deacetylated PGC-1α is more active and transactivates the 
transcription of genes encoding enzymes of fatty acid b-oxidation and gluconeogenesis. In 
fact, knock-down of SIRT1 in the liver leads to reduced glucose production and fatty acid 
oxidation in the liver, under fasting conditions189. These studies demonstrate that SIRT1 
regulates metabolic adaptation and that PGC-1α mediates most of SIRT1 effects. Finally, 
HDAC11 is the only member of class IV HDACs but its function is still poorly 
understood. 
 
 
Figure 6: Classification of mammalian HDACs. Adapted from Ferrari, 2012167 
 
Histone deacetylases regulate energy metabolism 
In recent years it has become clear that epigenetic changes, consequent to disruption of 
HAT or HDAC activity, are associated to several pathological conditions, such as 
cancer190, insulin resistance and diabetes. One of the first evidences of the involvement of 
HDACs in the pathogenesis of diabetes is a genome wide analysis showing significant 
linkage of HDAC2 located in the region 6q21 with both type 1 and type 2 diabetes 
loci191-193. No other mutations of HDACs have been so far reported, also for other 
diseases like cancer194 in which epigenetic regulation has been extensively studied in the 
last decade. Furthermore, several studies revealed that HDACs, in particular HDAC4 
and HDAC5, regulate the expression of metabolic genes in skeletal muscle195-197. 
Interestingly, a recent study by Gao and colleagues198 emphasized the involvement of 
HDACs in energy expenditure. They reported that sodium butyrate, a short chain fatty 
acid often found in the diet that inhibits class I and class II HDAC activity, improves 
metabolic dysfunction in diet-induced obese mice. These authors observed that 
supplementation with sodium butyrate increased energy expenditure and fatty acid 
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oxidation, and protected mice from high fat diet-induced insulin resistance. Sodium 
butyrate also enhanced thermogenic function and reduced fat accumulation and size of 
brown adipocytes. In skeletal muscles sodium butyrate increased the number of oxidative 
fibers and enhanced mitochondrial function. Indeed, in vivo butyrate is an activator of 
PGC-1α, the master regulator of mitochondrial biogenesis. Based on these results, the 
hypothesis is that butyrate, by inhibiting histone deacetylases, opens chromatin in the 
PGC-1α gene promoter thus inducing the transcription of this gene. However, butyrate is 
known to affect energy metabolism via other mechanisms199, as it has been shown to affect 
adipogenesis via HDAC-independent mechanisms181. Therefore it will be necessary to 
perform ad hoc studies with more specific inhibitors to better address the role of HDACs 
in energy metabolism in the context of obesity and type 2 diabetes. 
Another strong evidence demonstrating that epigenetic modifications regulate energy 
metabolism arises from a recent study by Yamamoto et al200, in which the authors showed 
that nuclear receptor corepressor 1 (NCoR1) is a regulator of muscle mass and its 
oxidative capacity. NCoR1 is a transcriptional corepressor that participates in the 
formation of repressive complexes, together with several HDACs, in particular HDAC3, 
HDAC4, 5, 7 and 9201. These authors demonstrated that muscle-specific loss of NCoR1 
in mice (NCoR1skm-/-) increase muscle mass, locomotor activity (i.e., mice run for a 
significantly longer time and distance) and oxygen consumption, with a reduction in the 
respiratory exchange ratio (RER), suggesting that they preferentially use fat as energy 
source. In line with these observations, they detected increased mitochondrial content and 
activity in the gastrocnemius of NCoR1skm-/-, with concomitant reduction of the 
number of glycolytic MyHC2b-positive fibers and increased number of oxidative 
MyHC2x- and 2a- positive fibers. Interestingly, these authors showed that the expression 
of MEF2 family members increases in skeletal muscle of NCoR1skm-/- mice and 
negatively correlates with NCoR1 levels. It should be mentioned that MEF2 could be 
acetylated and activated by the acetyltransferases p300/CBP, whereas HDAC3202, 
HDAC4, 5, 7 and 9181,203 and SIRT1204 interact with MEF2 and prevent its activation. 
Thus the absence of NCoR1 induces acetylation and activation of MEF2, leading to 
induction of MEF2 targets and to increased muscle mass. Moreover, NCoR1skm-/- mice 
show higher expression of genes related to mitochondrial respiration and fatty acid 
catabolism, whose expression in muscle is controlled by PPAR and estrogen related 
receptor (ERR) families205. It should be noted that NCoR1 is recruited to PPAR 
responsive elements (PPREs) in the Ucp3 promoter and to the extended nuclear receptor 
half-sites (NR1/2) that binds members of ERR family in the pyruvate dehydrogenase 
kinase 4 (Pdk4) promoter (Figure 5). In addition, histone 4 is hyperacetylated on these 
promoters in the absence of NCoR1, suggesting that under this condition the coactivator 
PGC-1α activates the transcription of these genes206. For this reason, loss of NCoR1 
phenocopies PGC-1α overexpression, in that both models show induction of 
mitochondrial fatty acid b-oxidation and improvement of exercise capacity207. A recent 
study by Li and collaborators208 demonstrated that NCoR1 also plays a key role in adipose 
tissue. PPARγ is highly expressed in this tissue and is a determinant of adipocyte 
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differentiation, as well as a regulator of insulin sensitivity and adipokine secretion209-212. 
However, the transcriptional regulation exerted by PPARγ depends on the multi-protein 
coregulatory complexes recruited on target gene promoters and NCoR1 is one of the most 
important corepressors also in this tissue. In the same study, they found that adipocyte-
specific NCoR1 knockout (NCoR1 AKO) mice become more obese than control mice 
when fed with high fat diet, due to increased subcutaneous and visceral adipose tissue 
mass. In epididymal white adipose tissue of NCoR1 AKO mice they detected increased 
expression of typical adipogenic genes such as Fas, Acc, Srebp1c, Scd1 and Scd2. 
Nonetheless, inflammation of adipose tissue is reduced, indicating improved functionality 
of this tissue and enhanced systemic insulin sensitivity. In adipose tissue, insulin promotes 
storage of free fatty acids into triglycerides and, consistently, authors observed reduced 
circulating levels of free fatty acids in NCoR1 AKO mice, suggesting a reduction of 
lipolysis in adipose tissue. Since it has been demonstrated that down-regulation of 
NCoR1 expression in 3T3-L1 cells enhances adipocyte differentiation in part by 
increasing PPARγ transcriptional activity213, Li and collaborators focused on the 
repressive effect of NCoR1 on PPARγ208. In this regard it should be mentioned that Choi 
et al.214 showed that high fat diet induces phosphorylation of PPARγ at serine 273, which 
dysregulates the expression of many genes of the adipogenic program. On the contrary, 
PPARγ agonists prevent phosphorylation at this site and allow the functional 
transcriptional cascade in adipose tissue. Consistently, in adipose tissue from NCoR1 
AKO mice serine 273 phosphorylation decreases, leading to increased expression of 
typical markers of adipocyte functionality.  
 
 
Figure 7: NCoR1 modulates transcription of oxidative genes in skeletal muscle; a) NCoR1 is 
recruited on the responsive element in the promoter of PPAR and ERR target genes forming a 
repressive complex and inhibiting the expression of these genes; (b) The ablation of NCoR1 leads 
to HDACs dissociation and to the recruitment of the acetyltransferases p300/CBP with the 
consequent derepression of target gene transcription. From Ferrari, 2012167 
 
A recent paper by Weems and coworkers215 demonstrated that class II HDACs regulate 
gene expression in adipocytes as a result of adrenergic activation. The authors observed 
that HDAC5 plays a central role in repression of the insulin-dependent glucose 
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transporter GLUT4 transcription in preadipocytes. Since it is known that repression of 
GLUT4 expression is correlated with insulin resistance in adipose tissue, this paper 
underlines the importance of HDACs in metabolic regulation and adipose tissue 
functionality. These authors also detected that, in the absence of HDAC5, other class II 
HDACs, including HDAC4 and HDAC9, may exert a redundant function. Moreover 
they demonstrated that cAMP-dependent down-regulation of GLUT4 mRNA 
expression in vivo is mediated by nuclear localization of HDAC4 and HDAC5: The 
Glut4 promoter contains an LXRE-binding site, and the cAMP signalling increases the 
recruitment of class II HDACs in this region, ultimately reducing Glut4 expression. 
HDACs also play a role in cardiac lipid metabolism and function. Recent evidence 
suggests that HDACs are important metabolic regulators in the heart. Postnatal 
inactivation of HDAC3 in both cardiac and skeletal muscle do not show cardiac 
dysfunction of mice fed with normal chow diet, whereas mice fed with high fed diet 
develop hypertrophic cardiomyopathy and heart failure. The reduced expression of genes 
encoding enzymes involved in fatty acid oxidation and lipid metabolism, typically 
observed in these mice, do not make them able to cope with the dietary lipid overload. 
These results demonstrate that efficient lipid catabolism is needed to maintain myocardial 
metabolic homeostasis and physiology, especially when fatty acids are the main fuel 
sources216. These results demonstrate that HDAC3 is required for cardiac metabolic 
regulation in response to a lipid enriched diet and that loss of HDAC3 compromises the 
ability of cardiac mitochondria to respond to nutritional changes and lipid overload. 
Histone deacetylases inhibitors 
Nowadays several HDAC inhibitors have been described; usually they are classified 
according to their chemical structure as short-chain fatty acids, hydroxamic acids, 
benzamides, ketones, and cyclic peptides with a pendant functional group. Unfortunately, 
most HDAC inhibitors, such as suberoylanilide hydroxamic acid (SAHA) and 
trichostatin A (TSA), inhibit HDAC isoforms non-specifically. Others, such as the 
benzamide MS-275, are more selective for class I HDACs. The therapeutic applications 
of HDAC inhibitors are multiple: in 2006, the US FDA approved SAHA for cutaneous 
manifestations of T-cell lymphoma. Many evidences suggest that HDAC inhibitors can 
be considered an interesting approach in cancer therapy. The DNA damage response is in 
fact modulated by the acetylation status of histone and non-histone proteins and HDACs 
protect cancer cells from genotoxic insults. Thus, HDAC inhibitors can silence DNA 
repair pathways, inactivate nonhistone proteins that are required for DNA stability and 
induce reactive oxygen species and DNA doublestrand breaks217. Recently, since HDACs 
play an important role in control of several cardiac events such as hypertrophy218, 
autophagy219, contractility220 HDAC inhibitors could represent a novel and promising 
therapy in patients with heart failure221. Moreover, other recent evidences underline the 
importance of tubulin acetylation mediated by HDAC6 in the development of 
Huntington222 and Parkinson diseases223. Based on these results, the HDAC class II
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selective inhibitors have been theorized as new avenues for therapeutic intervention in 
some neurodegenerative disorders224. Given the role of different HDACs in metabolic 
regulation, it is possible that in the future some specific inhibitors may find some clinical 
applications in lipid metabolic disorders. 
Histone deacetylases and adipocyte differentiation 
Lately, researchers have been trying to define the HDAC modification events regulating 
white pre-adipocyte proliferation and differentiation225,226. HDACs function in the related 
gene regulation signal pathways and networks of adipogenesis226-228. However, the actual 
role of some HDACs in adipogenesis is still unclear, since published literature provided 
evidences for both activating and repressing effect of HDACs in adipocyte differentiation. 
In a recent study, the canonical Class I HDACs 1 and 2 were shown to have a novel and 
unexpected role in the control of adipogenesis226. In this study, the authors used genetic 
deletion of both Hdac1 and Hdac2 in mouse embryonic fibroblasts and demonstrated a 
decrease in lipid accumulation following adipogenic induction of MEFs. Notably, 
deletion of each individual class I HDAC did not have an effect on the differentiation 
process, supporting the notion that HDAC1 and HDAC2 have redundant functions in 
this cellular process. Moreover the authors reported that treatment of 3T3-L1 
preadipocytes with the pan-HDAC inhibitors TSA, suberoylanilide hydroxamic acid 
(SAHA), or Scriptaid, led to a block in differentiation and adipogenesis, following 
induction226. Conversely treating 3T3-L1 cells with HDACs inhibitors sodium butyrate 
and valproic acid increased adipocyte differentiation227,229. The Class IIa specific inhibitor 
MC1568 was also recently shown to attenuate PPARγ-induced adipogenesis in 3T3-L1 
cells, while the Class I-selective inhibitor MS275 blocked adipogenesis completely in this 
cellular model230, consistent with other findings with TSA, SAHA and other HDAC 
inhibitors231-233. Interestingly a study by Chatterjee and coworkers demonstrated that class 
IIa HDAC9 has been implicated as a negative regulator in the control of adipogenesis 225. 
In this study, out of the eleven HDACs examined, only HDAC9 mRNA was down-
regulated during adipocyte differentiation. Downregulation of HDAC9 occurs relatively 
early and precedes the increase of expression of adipogenic genes during differentiation, 
suggesting that perhaps HDAC9 activity must decreased in order for adipogenesis to 
proceed. Pre-adipocytes from HDAC9 gene knock out mice exhibited accelerated 
adipogenic differentiation, whereas HDAC9 overexpression in 3T3-L1 pre-adipocytes 
suppressed adipogenic differentiation, demonstrating the direct role of HDAC9 as a 
negative regulator of adipogenesis.  
Literature suggested also HDAC3 as potential regulator of adipogenesis. It is in fact 
known that HDAC3 binds the NCoR1/SMRT co-repressor complex234. Moreover Yu 
and colleagues demonstrate that NCoR1 and SMRT decrease Pparγ transcriptional 
activity and repress 3T3-L1 adipogenesis, while Fajas and collaborators235 reported that 
HDAC3 by interacting with retinoblastoma forms a complex that inhibits Pparγ and 
adipocyte differentiation. These evidences suggested HDAC3 as a relevant regulator of 
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adipogenic program. In support of this idea, it has recently been reported that selective 
inhibition of HDAC3 promotes ligand-independent Pparγ activation by protein 
acetylation236.  
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Obesity is a severe metabolic disease, strictly associated to insulin resistance and type 2 
diabetes. Maintenance of glucose homeostasis depends on a complex interplay between 
the insulin responsiveness of skeletal muscle, liver, adipose tissue and glucose-stimulated 
insulin secretion by pancreatic beta cells. Defects in these organs are responsible for 
insulin resistance and progression to hyperglycemia. The westernization of the diet and 
sedentary lifestyle in the last decades increased incidence of obesity, characterized by 
uncontrolled expansion of an inflamed and not functional adipose tissue. As a 
consequence of this dis-metabolic state, the whole body homeostasis is disrupted, leading 
to several changes in the systemic milieu including the onset of hyperinsulinemia, elevated 
circulating free fatty acids and triglycerides, hyperglycemia, and the activation of systemic 
immune system, typical symptoms of type 2 diabetes. Thus the development of this 
pathological state compromised the functionality of all the important metabolic organs, 
such as liver, adipose tissues and skeletal muscle. In recent years, several studies 
highlighted the importance of epigenetics in metabolic regulation and in the 
pathophysiology of metabolic disorders. There is increasing evidence that epigenetic 
modifications are sensitive to environmental and nutritional cues. In fact, abnormalities in 
epigenetic regulation have been associated with multiple metabolic disorders, such as 
cardiovascular disease, obesity, and type 2 diabetes. These conditions are generally 
associated with defective lipid metabolism and decreased oxidative gene expression in key 
metabolic tissues. 
Epigenetic modifications allow cells to acquire heritable changes in gene function without 
inherent changes in the underlying coding sequence. In concert with differential 
transcription, epigenetic regulation enables identical cells to adopt multiple phenotypes.  
Acetylation of histone tails is one of the most common forms of chromatin modification. 
It is a dynamic process controlled by two families of enzymes. On the one hand, histone 
acetyltransferases (HATs) acetylate lysine residues of histones, thereby relaxing chromatin 
and enhancing entry of transcriptional complexes. On the other hand, histone 
deacetylases (HDACs) regulate gene transcription by removing the acetyl group from 
these lysine residues, thus compacting chromatin and making it less accessible to 
transcriptional activators. HDACs can also act upon transcription factors and cofactors to 
regulate their activity and they are recruited along with transcriptional coregulators to 
form repressive complexes that assemble at the promoters of target genes. Eighteen 
mammalian HDACs have been described; they are divided into four classes based on their 
homology to yeast HDACs.   
It has been demonstrated that HDACs play a role in the development and in the 
physiology of skeletal muscle, adipose tissue and liver. Furthermore, preliminary results 
obtained in our laboratory showed that in db/db mice, a genetic model of type 2 diabetes 
and obesity, class I HDAC inhibitor MS275 promotes oxidative metabolism, reduces 
body weight, increases energy expenditure, and enhances insulin sensitivity (data not 
shown). These effects are due to enhanced mitochondrial biogenesis in skeletal muscle, 
consistent with upregulation of Pgc-1α, the master regulator of mitochondrial biogenesis 
(Figure 8a), and increased functionality and oxidative capacity of adipose tissues as result 
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of activation of a Pgc-1α-Pparγ axis (Figure 8b). Moreover class I HDAC inhibitor 
MS275 causes a dramatic “browning” of white adipose tissue, as shown by higher 
expression of Ucp1 in visceral fat (Figure 8c).  
	  
Figure 8: a) Class I HDAC inhibitor induces Pgc-1α expression in skeletal muscle and adipose 
tissues; b) Class I HDAC inhibitor upregulates the master regulator of adipocyte differentiation 
Pparγ in visceral WAT and activates “browning” of this fat depot, by inducing Ucp1 expression. 
Statistical analysis: Student’s t test, *p<0.05, ***p<0.001. 
 
We used a cellular model of skeletal muscle, C2C12 myotubes, as a tool to understand the 
molecular events triggered by treatment with the class I HDAC inhibitor. We confirmed 
also in this cellular model that MS275 upregulates Pgc-1α expression (Figure 9a, white 
bars). Since we detected upregulation of Pgc-1α in cells and mice treated with the class I 
selective HDAC inhibitor, we hypothesized that this transcriptional coactivator may play 
a role in the effects exerted by MS275. In fact Pgc-1α silencing leads to a loss of 
responsiveness to the class I HDAC inhibitor in term of expression of Pgc-1α-regulated 
genes (Figure 9b).  
 
Figure 9: a) MS275 upregulates Pgc-1α and its main targets in C2C12 myotubes; b) Silencing of  
Pgc-1α determine a loss of responsiveness to MS275 treatment. Statistical analysis: Student’s t 
test, **p<0.01, ***p<0.001. 
 
It is known that Pgc-1α expression is regulated by HDAC1 and HDAC3, via CREB 
237and MEF2202 binding sites, respectively, located in the Pgc-1α promoter. However, we 
found that only Hdac3 silencing in C2C12 cells mimics the effects of MS275 (Figure 10), 
suggesting this HDAC isoform as key player in the mechanism of the class I selective 
HDAC inhibitor. 
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Figure 10: Silencing of Hdac3 but not of Hdac1 mimic the effects of the class I selective HDAC 
inhibition. Statistical analysis: Student’s t test, *p<0.05. 
 
Based on these preliminary results and on the published literature the goals of my PhD 
project were the investigation of the molecular mechanisms of class I selective HDAC 
inhibitor in skeletal muscle and adipose tissues, and the assessment of the contribution of 
these two organs to the phenotype induced by class I HDAC inhibition. To solve these 
open questions I used both in vivo and in vitro approaches:  I have investigated the effect 
of MS275 in a mouse model of diet-induced obesity that recapitulates the classical 
features of human obesity. In parallel I have examined in depth MS275 effect in different 
cellular models, including C2C12 myotubes and several adipose cell lines (primary brown 
adipocytes, 3T3-L1 preadipocytes and C3H10T1/2 mesenchymal stem cells). These 
approaches, integrated with preliminary results, lead us toward the hypothesis that 
HDAC3 could act as a key metabolic regulator in both skeletal muscle and adipose tissue. 
For this reason I also have generated two tissue-specific knock out models: skeletal muscle 
Hdac3 knock out (H3smKO) and adipose tissue Hdac3 knock out (H3atKO). By feeding 
these mice high fat diet I will characterize the metabolic effect of tissue specific deletion 
of HDAC3. Our study will improve the knowledge about the epigenetic regulation of 
metabolism in the context of diabetes and obesity. 
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Cell cultures 
C2C12 myotubes 
C2C12 myoblast are a subclone (produced by H. Blau, et al) of the mouse myoblast cell 
line established by D. Yaffe and O. Saxel. The C2C12 cell line differentiates rapidly, 
forming contractile myotubes and producing characteristic muscle proteins.  
Manteinance medium: Dulbecco's Modified Eagle's Medium. To make the complete 
growth medium, add fetal bovine serum to a final concentration of 10%, 1% L-Glutamine 
(Life Technologies) and 1% Pen/Strep (Life Technologies). 
Differentiation medium: Dulbecco's Modified Eagle's Medium. To make the complete 
growth medium, add horse serum to a final concentration of 2%, 1% L-Glutamine and 
1% Pen/Strep. 
Temperature: 37.0°C 
Subculturing protocol: remove and discard culture medium. Briefly rinse the cell layer 
with 0.25% (w/v) Trypsin- 0.53mM EDTA solution (Life technologies) to remove all 
traces of serum containing trypsin inhibitor. Add 3.0 ml of Trypsin-EDTA solution to 
flask and observe cells under an inverted microscope until cell layer is dispersed (usually 
within 5-7 minutes). Note: To avoid clumping do not agitate the cells by hitting or 
shaking the flask while waiting for the cells to detach. Cells that are difficult to detach 
may be placed at 37°C to facilitate dispersal. Add 7.0 ml of complete growth medium and 
aspirate cells by gently pipetting. Add appropriate aliquots of the cell suspension to new 
culture vessels. Inoculate at a cell concentration between 1.5 X 10 exp5 and 1.0 X 10 exp6 
viable cells/75 cm2. Incubate cultures at 37°C. 
Medium Renewal: Every two days. 
Differentiation protocol: Plate cells at the final concentration of 70000 cells/ml in 24, 12- 
or 6-well plates. Two days after plating, cells become confluent. Switch the medium with 
the differentiation medium and renew it every two days for 4 days. At the fifth day cells 
are completely differentiated. 
Treatment with HDAC inhibitor: After 5 days from the beginning of differentiation cells 
treated for 24 hours (ChIP assay) or for 48 hours (protein expression analysis) with 
vehicle DMSO or with 5µM MS275 (provided by professor Antonello Mai, Univeristà di 
Roma “La Sapienza”). 
Primary brown adipocytes 
Primary brown adipocytes were isolated from the stromal vascular fraction (SVF) of 
brown adipose tissue from 0-3 days old pups (C57BL6/J). From 1 pup is possible to 
obtain a suitable number of cells to cover 6 wells of a 12-well plate. 
Growth medium: Dulbecco’s Modified Eagle’s Medium. To make the complete growth 
medium, add fetal bovine serum to a final concentration of 20%, 1% L-Glutamine, 1% 
Pen/Strep, 20mM Hepes. 
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Induction medium: Dulbecco’s Modified Eagle’s Medium. To make the complete growth 
medium, add fetal bovine serum to a final concentration of 10%, 1% L-Glutamine, 1% 
Pen/Strep, 20mM Hepes, 1nM triiodotyronine, 5 µg/ml insulin, 5mM 3-isobutyl-1-
methylxanthine (IBMX, Sigma Aldrich), 2 µg/ml dexamethasone (Sigma Aldrich), 
0.25mM indomethacin (Sigma Aldrich). 
Differentiation medium: Dulbecco’s Modified Eagle’s Medium. To make the complete 
growth medium, add fetal bovine serum to a final concentration of 10%, 1% L-
Glutamine, 1% Pen/Strep, 20mM Hepes, 1nM triiodotyronine, 5 µg/ml insulin (insulin 
sodium salt, Sigma Aldrich). 
Isolation buffer: 3M NaCl, 0.154M KCl, 100mM CaCl2, 50mM Glucose, 1M HEPES, 
1% Pen/Strep, 4% Bovin Serum Albumin (BSA, Sigma Aldrich) 
Collagenase A (Roche): dissolved in isolation buffer.  
Isolation protocol: Remove brown adipose tissue (BAT) from the inter-scapular region of 
0-3 days old pups and put it a sterile plate, containing 500ul of sterile PBS 1X. Cut the 
tissue with sterile blade and collect the material from 2-3 mice in a 2ml eppendorf tube. 
Add 500ul of collagenase A (1.5 mg/ml). Vortex the tube and put in agitation for 40 min 
at 37°C. While cells are digesting, put 1ml/well of growth medium in 12-well plates. 
Filter the cellular suspension with 70µm cell strainer (BD Biosciences). Adjust the 
volume, based on the number of wells to plate. Aliquot 1ml/well of cellular suspension in 
12-well plates previously prepared. Incubate at 37°C.  
Differentiation protocol 
After 24 hours renew growth medium in order to eliminate debris. When cells reach 75-
80% of confluence, replace medium with induction medium for 48 hours. Replace 
medium with differentiation medium, and renew it every 48 hours till the cells are fully 
differentiated to mature brown adipocytes. 
Treatment with HDAC inhibitor: After 7 days from the beginning of differentiation cells 
were treated for 24 hours (mRNA expression analysis), for 48 hours (oxygen consumption 
analysis) or for 60 hours (mitochondrial DNA quantification) with vehicle DMSO or 
with 1µM MS275. 
C3H10T1/2 mesenchymal stem cells 
C3H/10T1/2, Clone 8 was isolated by C. Reznikoff, D. Brankow and C. Heidelberger in 
1972 from a line of C3H mouse embryo cells. 
Manteinance medium: Dulbecco's Modified Eagle's Medium. To make the complete 
growth medium, add fetal bovine serum to a final concentration of 10%, 1% L-Glutamine 
(Life Technologies) and 1% Pen/Strep (Life Technologies). 
Induction medium: Manteinance medium supplemented with 5 µg/ml insulin, 5mM 3-
isobutyl-1-methylxanthine (IBMX, Sigma Aldrich), 2 µg/ml dexamethasone (Sigma 
Aldrich), 5µM rosiglitazone (Cayman Chemicals).  
Differentiation medium: Manteinance medium supplemented with 5 µg/ml insulin. 
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Temperature: 37.0°C 
Subculturing protocol: remove and discard culture medium. Briefly rinse the cell layer 
with 0.25% (w/v) Trypsin- 0.53mM EDTA solution (Life technologies) to remove all 
traces of serum which contains trypsin inhibitor. Add 3.0 ml of Trypsin-EDTA solution 
to flask and observe cells under an inverted microscope until cell layer is dispersed (usually 
within 5-7 minutes). Note: To avoid clumping do not agitate the cells by hitting or 
shaking the flask while waiting for the cells to detach. Cells that are difficult to detach 
may be placed at 37°C to facilitate dispersal. Add 7.0 ml of complete growth medium and 
aspirate cells by gently pipetting. Add appropriate aliquots of the cell suspension to new 
culture vessels. Inoculate at a cell concentration between 1.5 X 10 exp5 and 1.0 X 10 exp6 
viable cells/75 cm2. Incubate cultures at 37°C. 
Medium Renewal: Every two days. 
Differentiation protocol: Plate cells at the final concentration of 70000 cells/ml in 12-well 
plates. Two days after plating, cells become confluent. Leave cells at confluence for 24 
hours; then switch the medium to induction medium for 3 days. Maintain cells in 
differentiation medium, renewing every other day, till the cells are completely 
differentiated.  
Treatment with HDAC inhibitor: C3H10T1/2 cells were treated with vehicle or with 
1µM MS275 from the beginning of differentiation, and all along the differentiation 
program (DMSO ind, MS275 ind), or were differentiated with the classic protocol and 
treated for 24 hours at the end of differentiation (DMSO p.d., MS275 p.d.). 
 
 
 
Figure 11: Experimental protocol for differentiation of C3H10T1/2 cells 
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3T3-L1 preadipocytes 
L1 is a continuous substrain of 3T3 (Swiss albino) developed throh clonal isolation. 
Manteinance medium: Dulbecco's Modified Eagle's Medium. To make the complete 
growth medium, add fetal bovine serum to a final concentration of 10%, 1% L-Glutamine 
(Life Technologies) and 1% Pen/Strep (Life Technologies). 
Induction medium: Manteinance medium supplemented with 5 µg/ml insulin, 5mM 3-
isobutyl-1-methylxanthine (IBMX, Sigma Aldrich), 2 µg/ml dexamethasone (Sigma 
Aldrich). 
Differentiation medium: Manteinance medium supplemented with 5µg/ml insulin. 
Temperature: 37.0°C 
Subculturing protocol: remove and discard culture medium. Briefly rinse the cell layer 
with 0.25% (w/v) Trypsin- 0.53mM EDTA solution (Life technologies) to remove all 
traces of serum which contains trypsin inhibitor. Add 3.0 ml of Trypsin-EDTA solution 
to flask and observe cells under an inverted microscope until cell layer is dispersed (usually 
within 5-7 minutes). Note: To avoid clumping do not agitate the cells by hitting or 
shaking the flask while waiting for the cells to detach. Cells that are difficult to detach 
may be placed at 37°C to facilitate dispersal. Add 7.0 ml of complete growth medium and 
aspirate cells by gently pipetting. Add appropriate aliquots of the cell suspension to new 
culture vessels. Inoculate at a cell concentration between 1.5 X 10 exp5 and 1.0 X 10 exp6 
viable cells/75 cm2. Incubate cultures at 37°C. 
Medium Renewal: Every two days. 
Differentiation protocol: Plate cells at the final concentration of 70000 cells/ml in 12-well 
plates. Two days after plating, cells become confluent. Leave cells at confluence for 48 
hours; then switch the medium to induction medium for 2 days. Maintain cells in 
differentiation medium, renewing every other day, till the cells are completely 
differentiated.  
Treatment with HDAC inhibitor: 3T3-L1 cells were treated with vehicle or with 1µM 
MS275 from the beginning of differentiation, and all along the differentiation program 
(DMSO ind, MS275 ind), or were differentiated with the classic protocol and treated for 
24 hours at the end of differentiation (DMSO p.d., MS275 p.d.). 
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Figure 12: Experimental protocol for differentiation of 3T3-L1 cells 
 
 
Electron microscopy in C2C12 cells 
 
Samples were fixed in 3% (wt/vol) glutaraldheyde in 0.1 M Sorensen phosphate buffer 
(pH 7.4) for 60 min at room temperature, rinsed and postfixed in 1% osmium tetroxide in 
0.1M Sorensen phosphate buffer, dehydrated through an ascending series of ethanols, and 
embedded in Durcupan (Sigma-Aldrich). Ultrathin sections were obtained with an 
Ultracut ultramicrotome (Reichert-Jung) and stained with uranyl acetate and lead citrate 
before undergoing examination with a JEOL JEM 1010 transmission electron 
microscope.were processed as previously described (14). Ultrathin sections (200 nm) were 
evaluated using a JEM 1010 TEM (Jeol). Bioptic fragments from gastrocnemius (2 3 2 
mm) were fixed in 3% glutaraldehyde in 0.1 mol/L Sorensen buffer, pH 7.4, overnight at 
4°C and Araldite embedded. Two micron semithin sections were stained with toluidine 
blue. Ultrathin sections (60 nm) were stained with lead citrate and uranyl acetate and 
examined with a Jeol CX100 TEM (Jeol). 
 
 
Oxygen consumption in primary brown adipocytes 
 
Cells (5x105) were detached (250µl Trypsin- 0.53mM EDTA solution/well); resuspended 
in PBS containing 25 mmol/L glucose, 1 mmol/L sodium pyruvate, and 2% fatty acidfree 
BSA; and transferred to a Clark-type oxygen electrode chamber at 37°C. After recording 
of basal respiration, uncoupled respiration was determined with oligomycin (2.5 mg/mL), 
and maximal respiration was induced with 2.4mmol/L carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone. Data were normalized to protein content. 
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RNA extraction and real-time qPCR  
 
Total RNA from primary brown adipocytes, C3H10T1/2 adipocytes and 3T3-L1 
adipocytes was double extracted with TRIzol Reagent® (Invitrogen), purified with 
commercial kit (Macherey-Nagel, Milano, Italia), and quantitated with Nanodrop 
(Thermo Scientific, Wilmington, DE). Total RNA from brown adipose tissue, white 
subcutaneous adipose tissue and white visceral adipose tissue was double extracted with 
Qiazol Reagent® (Qiagen), purified with commercial kit (RNeasy Lipid Tissue Mini kit, 
Qiagn), and quantitated with Nanodrop (Thermo Scientific, Wilmington, DE). Specific 
mRNA was amplified and quantitated by real time PCR, using iScriptTM One Step RT-
PCR for Probes (Bio-Rad, Milano, Italia), following the manufacturer’s instructions. 
Primer sequences are available on request. Data were normalized to 36B4 mRNA and 
quantitated setting up a standard curve. 
Experiments were performed in triplicate and repeated at least twice with different cell 
preparations. Primers for real-time PCRs were designed by IDT software avilable on line 
optimized to work in a one-step protocol (10 min at 50°C for reverse transcription, 40 
cycles of amplifications each consisting of a denaturation step at 95° C for 10 s and an 
annealing/extension step at 60° C for 30 s). The oligonucleotides used for real-time PCR 
were synthesized by or Eurofin MWG Operon (Ebersberg, Germany). Sequences were 
reported in table 1. 
 Primers and probes for Pparγ, Adrb3 and Prdm16 were from Applied Byosistems 
(unkown sequences). 
 
Gene  Sequences 
Pgc-1α 
Forward 
Reverse 
Probe 
CATTTGATGCACTGACAGATGGA 
GTCAGGCATGGAGGAAGGAC 
CCGTGACCACTGACA ACGAGGCC 
Tfam 
Forward 
Reverse 
Probe 
CACCCAGATGCAAAACTTTCAG 
CTGCTCTTTATACTTGCTCACAG 
CCACAGGGCTGCAATTTTCCTAACC 
CytC 
Forward 
Reverse 
Probe 
GAAAAGGGAGGCAAGCAT 
ACTCCATCAGGGTATCCTCT 
AACAAGAACAAAGGCATCACCTGGG 
Cox6a1 
Forward 
Reverse 
Probe 
GTTCGTTGCCTACCCTCAC 
TCTCTTTACTCATCTTCATAGCCG 
ACCATACCCTCTTCCACAACCCTCA 
Idh3α 
Forward 
Reverse 
Probe 
ACGGAAGGAGAATACAGTGG 
GTACTCGAAGGCAAACTCTG 
ACCCCATCAACGATCACATGCTCA 
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Suclg1 
Forward 
Reverse 
Probe 
AATGATCCAGCCACAGAAGG 
AGCAATGAAGGACACTACAGG 
AGCATAACTCAGGTCCAAAGGCCAA 
Ucp1 
Forward 
Reverse 
Probe 
GAGCTGGTAACATATGACCTC 
GAGCTGACAGTAAATGGCA 
ACAAAATACTGGCAGATGACGTCCC 
Dio2 
Forward 
Reverse 
Probe 
CTGTGTCTGGAACAGCTT 
CACTGGAATTGGGAGCAT 
CTAGATGCCTACAAACAGGTTAAACTGGGT 
Elovl3 
Forward 
Reverse 
Probe 
TGCTTTGCCATCTACACG 
CAGTGGACAAAGATGAGTGG 
TGAACTGGGAGACACGGCCTT 
Cidea 
Forward 
Reverse 
Probe 
CACGCATTTCATGATCTTGG 
CCTGTATAGGTCGAAGGTGA 
TTACTACCCGGTGTCCATTTCTGTCC 
Glut4 
Forward 
Reverse 
Probe 
TGTCGCTGGTTTCTCCAACTG 
CCATACGATCCGCAACATACTG 
ACCTGTAACTTCATTGTCGGCATGGGTTT 
Acrp30 
Forward 
Reverse 
Probe 
AGGCATCCCAGGACATC 
CCTGTCATTCCAACATCTCC 
CCTTAGGACCAAGAAGACCTGCATCTC 
Fabp4 
Forward 
Reverse 
Probe 
GGCGTGGAATTCGATGAA 
GCTTGTCACCATCTCGTT 
TGATGCTCTTCACCTTCCTGTCGT 
Pepck 
Forward 
Reverse 
Probe 
TTGAACTGACAGACTCGCCCT 
TGCCCATCCGAGTCATGA 
CCGCATGCTGGCCACCACA 
Plin 
Forward 
Reverse 
Probe 
ACAGACACAGAGGGAGAGG 
AGTGTTCTGCACGGTGTG 
AGGAGGAAGAAGAGTCCGAGGCT 
C/EBPα 
Forward 
Reverse 
Probe 
AGAGCCGAGATAAAGCCAAAC 
TCATTGTCACTGGTCAACTCC 
AGCACCTTCTGTTGCGTCTCCA 
C/EBPβ 
Forward 
Reverse 
Probe 
CCCCGCGTTCATGCA 
CAGTCGGGCTCGTAGT 
ACTTCCATGGGTCTAAAGGCG 
Cpt1b 
Forward 
Reverse 
Probe 
GATGCAGTTCCAGAGAATCC 
CTTGTTCTTGCCAGAGCT 
TCTGCCCACTCTACCCTTCCTC 
Acadl 
Forward 
Reverse 
Probe 
GAAACCAGGAACTACGTGAAG 
GCTGTCCACAAAAGCTCT 
CACACATACAGACGGTGCAGCATA 
CD36 
Forward 
Reverse 
Probe 
GCGACATGATTAATGGCACAG 
GATCCGAACACAGCGTAGATAG 
CAACAAAAGGTGGAAAGGAGGCTGC 
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Hsl 
Forward 
Reverse 
Probe 
GCTCCCTTTCCCCGA 
ATGCAGAGATTCCCACCT 
CACTGTGACCTGCTTGGTTCAACT 
Atgl 
Forward 
Reverse 
Probe 
TCGTGTTTCAGACGGAGA 
CACATAGCGCACCCCT 
TGCAGACATTGGCCTGGATGAG 
Fasn 
Forward 
Reverse 
Probe 
TCGTGATGAACGTGTACCGG 
CGGGTGAGGACGTTTACAAAG 
TGCCTTCCGTCACTTCCAGTTAGAGCA 
36b4 
Forward 
Reverse 
Probe 
AGATGCAGCAGATCCGCAT 
GTTCTTGCCCATCAGCACC 
CGCTCCGAGGGAAGGCCG 
 
Table 1: Primers and probes sequences 
 
 
Chromatin immunoprecipitation assay 
 
In vitro chromatin immunoprecipitation 
C2C12 myotubes (6 wells plate, 3 wells for each condition) were fixed with fixation buffer 
(500mM Hepes/KOH pH 7.9, 0.1M NaCl, 1mM EDTA pH 8, 0.5mM EGTA pH 8, 
11% Formaldehyde) and incubate 10 minutes. Wells were washed with PBS and collected 
using cell scraper. Pool cells from 3 wells in a 15 ml falcon and centrifuge 1000rpm, 5 min 
at 4°C. Pellets were lysed with 300µl of lysis buffer (50mM Tris pH 8.0, 5mM EDTA, 
1% SDS, protein inhibitor), and sonicated. DNA was quantified by using NanoDrop 
(Thermo scientific). 150µg of sample were immunoprecipitated with Anti-HDAC3 o 
Anti IgG antibody overnight. After the immunoprecipitation protein-antibody complexes 
were precipitated with Dynabeads (Invitrogen), washed twice with WB I (20mM Tris pH 
7.4, 150mM NaCl, 0.1% SDS, 1% Triton-X100, 2mM EDTA), once with WB II 
(20mM Tris pH 7.4, 250mM NaCl, 0.1% SDS, 1% Triton-X100, 2mM EDTA), twicw 
with Tris-EDTA buffer and eluted with elution buffer (0.1M NaHCO3, 1% SDS). 
Cross link reversion was carried out by overnight incubation at 65°C. Samples were 
incubated with proteinase K (0.1 mg/ml) for 1 hour at 55 °C. DNA was purified with 
Quiaquick spin columns (Qiagen). HDAC3 recruitment on Pgc-1a promoter was 
quantified by SyberGreen (BioRad) real time qPCR. 
 
In vivo chromatin immunoprecipitation 
Skeletal muscle and brown adipose tissue from db/db mice were dissected and fragmented 
in small pieces, and fixed in 0.5% paraformaldehyde for 10 minutes. Fixing was blocked 
by 125mM glycine. Samples were centrifuged 1000rpm, 5 min at 4°C. Pellets were lysed 
in lysis buffer (50mM Tris pH 8.0, 5mM EDTA, 1% SDS, pritein inhibitor), and 
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sonicated. The protocol of in vitro chromatin immunoprecipitation was followed also for 
tissue samples. 
 
 
Protein extraction and Western Blot analysis 
 
Lysis 
C2C12 myotubes and C3H10T1/2 adipocytes cultured in 6-well plate were lysed with 
300 µl of SDS sample buffer (62.5 mM Tris- HCl pH 6.8, 2% w/v SDS, 10% glycerol, 50 
mM DTT, 0.01% w/v bromophenol blue). 
Brown adipose tissue (50 mg) was lysed in 500 µl of SDS sample buffer. 
 
Solutions and Reagents 
Running buffer: 25 mM Tris base, 192 mM glycine, 3.5mM SDS 
Transfer Buffer: 25 mM Tris base, 192 mM glycine, 20% methanol (pH 8.5). 
Tris Buffered Saline (TBS): 20mM Tris ph 7.5, 150 mM Nacl. 
Blocking Buffer: 1X TBS, 0.1% Tween-20 with 5% w/v nonfat dry milk  
Wash Buffer: 1X TBS, 0.1% Tween-20 (TBS/T). 
Antibody Dilution Buffer: 1X TBS, 0.1% Tween-20 with 5% nonfat dry milk as indicated 
on primary antibody datasheet 
 
Electrophoresis and protein Blotting 
Proteins are run for 2 hours at a constant voltage (90 V) in polyacrylamide gel (10% or 
15% polyacrylamide). 
Protein are electro-transferred (300 mA for 2 hours) on nitrocellulose or PVDF 
membrane. 
Membrane blocking and antibody incubations: incubate membrane in 25 ml of blocking 
buffer for one hour at room temperature. Wash three times with 15 ml of TBS/T.  
Primary antibody incubation: incubate membrane and primary antibody (at the 
appropriate dilution as recommended in the product datasheet) in 10 ml primary antibody 
dilution buffer with gentle agitation overnight at 4°C. 
Wash three times with TBS/T. 
Incubate membrane with the species appropriate HRP-conjugated secondary antibody for 
1h at room temperature with gentle agitation. 
Wash three with TBS/T. 
Detection of proteins: incubate membrane with appropriate volume of SuperSignal West 
Pico Chemiluminescent Substrate (Pierce Thermo Scientific) for 5 minutes. 
Drain membrane of excess developing solution, wrap in plastic wrap and expose to x-ray 
film.  
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Primary antibodies 
Cocktail OXPHOS (MitoSciences), 1:250 in 5% nonfat dry milk 
Ucp1 antibody (Abcam), 1:1000 in 5% nonfat dry milk  
Pparγ antibody (Santa Cruz), 1:200 in 5% nonfat dry milk 
 
Secondary antibodies 
Anti Mouse, 1:4000 in 5% nonfat dry milk for OXPHOS 
Anti Mouse, 1:5000 in 5% nonfat dry milk for Ucp1 
Anti Rabbit, 1:5000 in 5% nonfat dry milk for Pparγ 
 
 
Glycerol release  
 
At the end of experiment, cell culture medium from C3H10T1/2 cells grown and 
differentiated in 12-well plates was collected. Glycerol release in cell medium, as an index 
of fatty acids beta-oxidation, was measured with Triglyceride Dosage Kit (Sentinel). 
 
 
Oil red O staining 
 
Medium was aspirated from wells and they were washed with 1 ml of 1X PBS. 
Cells were fixed with 1ml of 10% formalin for at least 1 hour and then washed with 1ml 
of water. 1ml 60% isopropanol was added to cover the bottom of each well and let sit for 
2-5 minutes. Cells were then stained with Oil Red O solution; after 10 minutes 
incubation wells were washed 3 times with 1 ml of water. Pictures were taken at 20X 
magnification using Axiovert Microscope (Zeiss).  
For Oil Red O quantification, staining was eluted from wells with 1.5ml of 100% 
isopropanol (10 minutes incubation) and absorbance was measured (500 nm, 0.5 sec 
reading). 
 
 
Animal studies 
 
Diet induced obese wild type mice 
C57BL6/J male mice were purchased from The Jackson Laboratory. Six-week-old male 
mice were randomized into two groups according to glucose levels and body weight and 
fed high fat diet (HFD, 60% calories from fat, Research Diet, D12492) for 17 weeks, 
monitoring body weight and fasting glycemia. From week 18 mice were treated for 23 
days every other day with intraperitoneal (i.p.) injection of vehicle (DMSO) or of MS275 
(10mpk). 
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MS275 was dissolved in DMSO and stored at +4°C. Prior to use, the solutions were 
warmed in a 42°C water bath with agitation. For blood analysis, db/db mice were fasted 
for 16 hr and blood was collected from the tail vein. Glucose levels were determined using 
an Accu-Chek Active glucometer (Roche). Triglyceride and cholesterol levels were 
determined by the Plasma Triglyceride Kit (Sentinel) and by the Plasma Cholesterol Kit 
(Sentinel). Insulin levels were determined using an AlphaLISA® Human Insulin 
Research Immunoassay Kit (Perkin Elmer). Adiponectin and Leptin levels were 
determined using ELISA assay Kits (Genway).  
For glucose tolerance tests, mice were fasted for 16 hours, and glucose levels from tail-
vein blood were determined before and 30, 60, 90, and 120 min after i.p. injection of 
glucose (2 g/kg). At the end of treatments, brown and white fat (subcutaneous and 
visceral), liver and blood samples were collected from individual animals. 
For cold challenge tests, basal rectal temperature was measured at 24°C. Then mice were 
housed for 140 minutes at 4°C and rectal temperature was measured every 20 minutes. 
 
Diet induced obese knock out mice 
Eight-weeks-old weeksHdac3 skeletal muscle knock out (H3smKO) mice and their Cre-
/- littermates (Floxed), and eight-weeks-old Hdac3 adipose tissue knock out (H3atKO) 
mice and their Cre-/- littermates (Floxed), were fed high fat high sucrose diet (HFHSD, 
45% calories form fat, Research Diet, D12451) for 16 weeks. Body weight was measured 
every 2 weeks. 
Animal studies were conducted strictly following regulations of European Community 
(Directive 2010/63/EU) and local regulations for animal care (Decreto Legislativo 4 
marzo 2014, n. 26). 
 
 
Magnetic resonance imaging  
 
At day 18 of treatment, mice were anesthetized and analyzed in a 4.7 Tesla Avance II 
magnetic resonance imaging (MRI) scanner (Bruker Corporation). After a gradient-echo 
scout, 16 axial 1-mm-thick T1-weighted slices were placed in the abdominal region 
spanning from kidneys to bladder inclusive. The field of view was 30 X 30 mm2 with a 
matrix of 128 X 128 pixels. Four averages of a spin echo sequence with time to echo 10 
ms and time of repetition 400 ms were acquired in 3’25”. The slice immediately frontal 
with respect to the ilium bone was chosen for visceral fat estimation and was computed as 
follows: (fat area)/(slice area). Areas were measured with Photoshop (Adobe Systems). 
 
 
Histological analysis of adipose tissues 
 
Brown adipose tissue, subcutaneous white adipose tissue, visceral white adipose tissue and 
liver were fixed with Carnoy solution (6 parts 100% Ethanol, 3 parts chloroform 1 part 
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glacial acetic acid) for 24 hours at 4°C. Tissues were then transferred in 100% ethanol. 
Tissues were embedded in paraffin and 8µm sections were stained with hematoxylin-
eosin. Images were taken at X20 magnification. Cell size of adipocytes from white adipose 
tissues sections were quantified using the software Photoshop CS6 (Adobe Systems Inc., 
San Jose, California), by converting pixel number in surface units, and correcting for 
magnification.  
 
 
Liver fatty acids quantification by mass spectrometry analysis 
 
Liver from diet induced obese mice treated with vehicle or with MS275 were 
homogenized in methanol with tissue lyser (Qiagen). For the quantitative analysis of fatty 
acids, aliquots of methanolic extracts after addition of internal standards (heneicosanoic 
acid, Sigma-Aldrich), were subjected to acidic hydrolysis. Extracts were resuspended in 
chloroform-MeOH 1:2, v/v. 1N HCl:MeOH (1:2, v/v) was added to the total lipid 
extract and centrifuged at 150 rpm for 30 minutes. chloroform-water (1:1, v/v) was added, 
and the extracts were shaken. The lower organic phase was collected, split, transferred 
into tubes and dried under nitrogen flow. For fatty acids quantification the aliquot was 
suspended in 500ul of MeOH, diluted and transferred into 96-well plate and placed in an 
auto-sampler for LC-MS/MS analysis. Quantitative analysis was performed with 
calibration curves prepared and analyzed daily by electrospray ionization (ESI) using an 
API 4000 triple quadrupole instrument (AB Sciex, USA). The LC mobile phases were: 
water/10 mM isopropylethylamine/15mM acetic acid (phase A) and MeOH (phase B). 
The gradient (flow rate 0.5 ml/min) was as follows: T 0: 20% A, T 20: 1% A, T 25:1% A, 
T 25.1: 20% A, T 30: 20% A. The Hypersil GOLD C8 column (100 mm × 3 mm, 3m) 
was maintained at 40◦C. The API4000 was operated in negative electrospray mode and 
the compounds were detected in single ion monitoring (SIM).   
 
 
Generation of Hdac3 tissue specific knock-out 
 
To generate tissue specific knock out it has been used Cre-LoxP technology. To obtain 
specific deletion of Hdca3 in skeletal muscle, we crossed Hdac3 floxed mice in BL6 
background (provided by dr. Hiebert, Vanderbilt Univesity) with B6.Cg-Tg(ACTA1-
cre)79Jme/J (The Jackson Laboratory), expressing Cre under the control of promoter of 
the gene encoding for alpha skeletal muscle actin. To obtain specifc deletion of Hdac3 in 
adipose tissues we crossed Hdac3 floxed mice with B6;FVB-Tg(Adipoq-cre)1Evdr/J 
(The Jackson Laboratory), expressing Cre under the control of the promoter of the gene 
encoding for adiponectin. Breeding strategy is reported in Figure… 
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Figure 13: Breeding strategy to generate Hdac3 tissue specific knock out 
 
Genotyping  
Tail samples were digested in proteinase K 56°C overnight. Tail DNA was extracted with 
NucleoSpin Tissue kit (Macherey Nagel).  
Primers for Cre amplification: 
Transgene Forward: GCGGTCTGGCAGTAAAAACTATC   
Transgene Reverse: GTGAAACAGCATTGCTGTCAC TT   
Internal Positive Control Forward: CTAGGCCACAGAATTGAAAGATCT  
Internal Positive Control Reverse: GTAGGTGGAAATTCTAGCATCATCC 
Primers for LoxP amplification: 
Forward: CTCTGGCTTCTGCTATGTCAATG 
Reverse: GGACACAGTCATGACCCGGTC 
Thermal protocol for Cre PCR: 
→ 1 cycle:        94°C for 3minutes 
→ 35 cycles:     94°C for 30 seconds 
                          55°C for 30 seconds 
                          72°C for 45 seconds 
→ 1 cycle:        72°C for 2 minutes 
After PCR amplification, samples were run on 3% TAE gel.  
Thermal protocol for LoxP PCR: 
→ 1 cycle:        94°C for 5 minutes 
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                    55°C for 1 minute 
                    72°C for 1.5 minutes 
→ 35 cycles:     94°C for 1 minute 
                    55°C for 45 seconds 
                    72°C for 1.5 minutes 
→ 1 cycle:        72°C for 10 minute 
After PCR amplification, samples were run on 2% TAE gel. 
Expected bands: 
Cre: positive ctrl band = 324 bp 
          Cre positive band = 100 bp 
LoxP: floxed band = 504 bp 
            Wild type band = 464 bp 
 
 
Statistical Analysis 
 
Statistical analyses were performed by Student’s t test for the comparison of two different 
experimental groups or one-way ANOVA with the indicated post-test for multiple 
testing comparisons. All statistical analyses were performed using GraphPad (GraphPad 
Software). 
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Class I HDAC inhibitor MS275 promotes mitochondrial biogenesis in a 
cellular model of skeletal muscle 
 
It has been reported that HDACs are involved in the conversion of glycolytic to oxidative 
fibers that differ in the number of mitochondria. Our preliminary results showed in cells 
and mice increased expression of the master regulator of mitochondrial biogenesis Pgc-1a 
upon MS275 treatment. In order to investigate further how class I HDAC inhibition 
affects mitochondrial morphology and function, in collaboration with Dr. Donetti (Dip. 
Morfolgia Umana, Università degli Studi di Milano) we performed transmission electron 
microscopy analysis in C2C12 myotubes treated with vehicle or with the class I HDAC 
inhibitor. The ultrastructural appearance of mitochondria in vehicle treated cells was 
characterized by a dense matrix and well-organized cristae with dilated intracristae spaces. 
MS275 treated cells showed increased mitochondrial density and greater electron opacity 
of the matrix typical of metabolically active cells (Figure 14). 
 
	  
 
Figure 14: Representative electron microphotographs of ultrathin sections of C2C12 monolayers. 
Treatment with MS275 resulted in an increase in mitochondrial density and greater electron 
opacity of the matrix to the detriment of the development and organization of cristae. (Bar: 
500nm). 
 
These changes were paralleled by increased expression of the protein complexes of the 
electron transport chain (Figure 15). 
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Figure 15: Western blot analysis of mitochondrial complexes I–V of the electron transport chain 
in C2C12 myotubes treated with HDAC inhibitor for 48 h. 
 
 
Class I HDAC selective inhibitor reduces Hdac3 recruitment on Pgc-1α 
promoter in muscle 
 
Previous experiment demonstrated that Hdac3 inhibition recapitulated the effect of class I 
HDAC inhibitor in term of expression of Pgc-1α and its main targets. In order to deepen 
the molecular mechanism whereby MS275 by inhibiting Hdac3 remodel metabolic 
profile, we performed a chromatin immunoprecipitation analysis. Interestingly I found a 
reduced Hdac3 recruitment in MEF region in Pgc-1α promoter, in C2C12 myotubes and 
in skeletal muscle gastrocnemius from db/db mice treated with the class I selective 
inhibitor (Figure 16). 
	  
Figure 16: Treatment with MS275 reduced Hdac3 recruitment in Pgc-1α promoter leading to 
the transcriptional de-repression of this gene. Statistical analysis: Student’s t test, *p<0.05, 
***p<0.001. 
 
 
Class I HDAC inhibition in primary brown adipocytes activates 
mitochondrial biogenesis and mitochondrial function 
 
Previous experiment performed in our laboratory showed that db/db mice treated with 
MS275 were able to better counteract the reduction of body temperature during an acute 
cold exposure (data not shown). The tissue mostly involved in the regulation of body 
temperature via non-shivering thermogenesis is brown adipose tissue (BAT). We 
hypothesized that the class I HDAC inhibitor potentiates oxidative metabolism, along 
with increased mitochondrial thermogenesis, as a result of the uncoupling of electron 
transport chain to oxidative phosphorylation in this tissue. To test this hypothesis we 
isolated primary brown adipocytes and we treated them with vehicle DMSO or with 
MS275: class I selective inhibitor increased gene expression of the gene encoding for 
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uncoupling protein 1 (Ucp1), the most important marker of BAT, and of the beta 3 
adrenergic receptor (Adrb3), key player in the activation of thermogenesis in response to 
SNS adrenergic stimulation (Figure 17). Moreover, upon MS275 treatment, we detected 
a significant increase of the expression of typical markers of mitochondrial biogenesis 
(Pgc-1α, Tfam), and adipose tissue functionality such as the master regulator of adipocyte 
differentiation Pparγ. In this cell line MS275 also upregulated genes involved in oxidative 
metabolism, such as the dehydrogenase for the long-chain acyl-CoA Acadl, the fatty acid 
transporter Cd36, the α subunit of isocitrate dehydrogenase Idh3α and subunit VIa of the 
cytochrome C oxidase Cox6a1 (Figure 17). 
 
Figure 17: Gene expression profile in primary brown adipocytes treated with vehicle or MS275 
1uM for 24 hours. Statistical analysis: Student’s t test, *p<0.05, ***p<0.001. 
 
To prove that class I HDAC inhibition promotes mitochondrial biogenesis in BAT, we 
analyzed mitochondrial DNA content in primary brown adipocytes and we detected a 
significant increase in MS275 treated cells. Moreover we analyzed oxygen consumption in 
cultured cells and we found that the class I HDAC inhibitor MS275 significantly 
increased basal, uncoupled and maximal respiration (Figure 18). 
 
 
Figure 18: a) Mitochondrial DNA content in primary brown adipocytes treated with vehicle or 
with MS275. b) Oxygen consumption measured in basal, uncoupled (2.5 uM oligomycin), 
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maximal (2.5 uM CCCP) condition in primary brown adipocytes treated with MS275 for 24 
hours. Statistical analysis: Student’s t test, **p<0.01, ***p<0.001. 
 
 
Class I HDAC inhibition reduces Hdac3 recruitment on Pgc-1α promoter 
in brown adipose tissue 
 
Having identified Hdac3 at the crossroad of the effects of class I HDAC selective 
inhibitor in skeletal muscle, we hypothesized that HDAC3 also plays a key role in brown 
adipose tissue. Chromatin immunoprecipitation of Hdac3 in brown adipose tissue from 
db/db mice revealed in fact a reduced recruitment of Hdac3 in PPRE region in Pgc-1α 
promoter (Figure 19). This result explained the upregulation of Pgc-1α expression 
detected in BAT of db/db mice treated with MS275 (see preliminary data). Pgc-1α along 
with Pparγ and other transcriptional coactivators are recruited on the PPRE in the Ucp1 
promoter, leading to transcription activation of this gene. Accordingly, we detected higher 
expression of Ucp1 (both at mRNA and protein level) in BAT from MS275-treated mice  
(Figure 16). 
 
Figure 19: ChIP assay on BAT from db/db mice showed a reduced recruitment of Hdac3 on Pgc-
1α  promoter in response to MS275 treatment. Consequently we detected increased expression of 
Ucp1 at mRNA and protein level. Statistical analysis: Student’s t test, **p<0.01, ***p<0.001. 
 
 
Hdac3: key regulator of oxidative metabolism? 
 
Results obtained in db/db mice and cells treated with the class I selective inhibitor 
demonstrated that class I HDACs strongly influence energy metabolism in skeletal 
muscle and adipose tissue, suggesting Hdac3 as key metabolic regulator.  To assess the 
contribution of skeletal muscle and adipose tissues to the phenotype induced by class I 
selective HDAC inhibitor and to investigate further the metabolic role of Hdac3, during 
my doctorate I have generated two mouse models: Hdac3 selective knock out in skeletal 
muscle and in adipose tissue. The purpose is to investigate the metabolic effect of Hdac3 
deletion in obesity.To this end, treatment of tissue specific Hdac3 ko mice with a high fat 
diet (60% calories from fat) to make knock out mice obese and insulin resistant are 
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currently under way. The results in knock out mice will be compared with results obtained 
upon a biochemical inhibition of class I HDACs with MS275. 
 
 
Inhibition of class I HDACs improves obese phenotype 
 
We investigated whether inhibition of class I HDACs could counteract obesity and 
insulin resistance in a mouse model of diet-induced obesity (DIO mice). We fed 6-week-
old male C57BL/6 mice a high fat diet (HFD, 60% kcal). After 16 weeks on HFD mice 
were randomized in two groups, without statistically significant difference in weight and 
glycemia. Mice were treated for 22 days, every other day, with vehicle DMSO or with the 
class I selective HDAC inhibitor MS275 10mg/kg/d, since our previous results 
demonstrated that at this dose the compound retained its class-selective inhibitory 
activity238. Starting from day 16 of treatment, MS275 treated mice showed lower body 
weight (Figure 20a), reaching 10% reduction at day 22 (Figure 20b), with no changes in 
daily food consumption (Figure 20c).  
 
Figure 20: a) Body weight loss in DIO mice treated with MS275 for 22 days, b) Body weight at 
day 22 in vehicle- and MS275-treated mic,e c) Food consumption 22 in vehicle- and MS275-
treated mice. Statistical analysis: Student’s t test, *p<0.05. 
 
Glucose tolerance test showed that treatment with MS275 improved glucose clearance in 
diet induced obese mice (Figure 21a). Plasma insulin and adiponectin levels at the end of 
the experiment did not show differences in two groups of mice (Figure 21b). However, we 
detected decreased level of circulating leptin (Figure 21b), suggesting amelioration of 
leptin resistance.  
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Figure 21: a) Glucose tolerance test in DIO mice treated with vehicle or MS275 performed after 
16 days of treatment, b) Plasma levels of insulin, adiponectin and leptin in the two groups of 
mice. Statistical analysis: Student’s t test, *p<0.05, **p<0.01. 
 
Surprisingly, we observed no changes of circulating levels of triglycerides and cholesterol 
(Figure 22a). Hematoxylin and eosin staining highlighted reduced lipid accumulation in 
liver of MS275-treated mice (Figure 22b), confirmed by mass spectrometry analysis 
showing a reduction of total hepatic fatty acids (Figure 22c). In particular it has been 
found a significant decrease of oleic acid, stearic acid, docosahexanoic acid and 
arachidonic acid. This last one particularly correlates with hepatic inflammation, thus my 
results suggested an amelioration of liver phenotype in MS275 treated mice. 
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Figure 22: a) Cholesterol and triglycerides levels in plasma from vehicle- and MS275-treated 
mice, b) Hematoxylin and eosin staining in liver from the groups of mice, c) Hepatic fatty acids 
measured by mass spectrometry. Statistical analysis: Student’s t test, *p<0.05, **p<0.01, ***p<0.001 
 
 
Class I HDAC inhibition improves brown adipose tissue functionality 
 	  
Since previous results in db/db mice have demonstrated that class I HDAC inhibition 
increased heat production238, we tested whether treatment with MS275 could affect 
thermogenic capacity in diet induced obese mice: after an acute exposure to 4°C MS275-
treated mice could better cope the cold challenge (Figure 23a). Brown adipose tissue 
(BAT) controls body temperature via non-shivering thermogenesis. Magnetic resonance 
imaging (MRI) of interscapular area showed that BAT mass was not affected by 
treatment (Figure 23b).  
	  
Figure 23: a) Cold challenge showed that MS275 stimulated thermogenesis, b) MRI analysis 
showing that BAT mass was not significantly different in two groups of mice. Statistical analysis: 
Student’s t test, *p<0.05. 
 
Nevertheless, hematoxylin and eosin staining showed that in control mice brown 
adipocytes were large, with big lipid droplets, typical of BAT from obese mice, which 
becomes less functional. In MS275-treated mice brown adipocytes were smaller and 
multilocular (Figure 24a), suggesting that even though BAT mass was not increased, the 
global phenotype of this tissue improved. Accordingly we detected increased expression of 
typical BAT markers Dio2 and Elovl3. Interestingly MS275 did not induce expression of 
Ucp1, which plays a key role in the thermogenic program (Figure 24b). 
Total Hepatic 
Fatty Acids
HFD MS275 0
100
200
300
400
*
ng
 / 
m
g 
liv
er
Linoleic acid
(18:2 n-6)
HFD MS275 0
1
2
3
4 **
ng
 / 
m
g 
liv
er
Oleic acid
(18:1 n-9)
HFD MS275 0
10
20
30
*
ng
 / 
m
g 
liv
er
Stearic acid
(18:0)
HFD MS275 0
20
40
60
80
*
ng
 / 
m
g 
liv
er
Docosahexaenoic acid
(22:6 n-3)
HFD MS275 
0.5
1.0
1.5
0
***
ng
 / 
m
g 
liv
er
Arachidonic acid
(20:4 n-6)
HFD MS275 0
1
2
3
***
ng
 / 
m
g 
liv
er
c) 
% BAT
HFD MS275 
0
1
2
3
4
5
%
 B
A
T 
/ t
ot
al
 s
ec
tio
n 
0 20 40 60 80 100 120 140
34
35
36
37
38
HFD
MS275 
*
*
Cold Challenge
Minutes
Bo
dy
 T
em
pe
ra
tu
re
 (°
C)
a)  b) 
	   Results	  
51	  
	  
 
Figure 24: a) Hematoxylin and eosin staining of BAT from DIO mice treated with vehicle or 
MS275, b) Gene expression of brown adipose tissue markers. Statistical analysis: Student’s t test, 
**p<0.01. 
 
 
MS275 reduces white adipose tissue mass and adipocyte size 
 
Magnetic resonance imaging (Figure 25a) of abdominal section of vehicle- and MS275-
treated mice showed 22% reduction of total white adipose tissue (WAT) mass as an effect 
of MS275 treatment (data not shown). The reduction detected in WAT mass was mostly 
due to reduced area of subcutaneous WAT (subWAT) since there was mild but not 
significant decrease of visceral WAT (viscWAT) (Figure 25b). Staining of inguinal 
subWAT (Figure 25c) and mesenteric viscWAT (Figure 25d) indicated that MS275 
significantly reduced both subcutaneous and visceral adipocyte size. 
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Figure 25: a) Representative images from MRI analysis, b) Quantification of visceral and 
subcutaneous WAT area normalized on total section area, c) H&E staining and cell size 
measurement of subcutaneous WAT sections d) H&E staining and cell size measurement of 
visceral WAT sections. Statistical analysis: Student’s t test, *p<0.05, ***p<0.001, n=5. 
 
 
Inhibition of class I HDACs promotes lipid oxidation and a brown like 
phenotype in white fat 
 
Gene expression analysis of WAT showed that MS275 upregulated the expression of 
typical adipocyte markers, such as Pparγ, Glut4, Fabp4 and Acrp30 (Figure 26a, b) in both 
subWAT and viscWAT, suggesting improvement of white fat functionality. In addition 
in WAT from MS275-treated mice we noticed higher expression of genes involved in 
triglycerides catabolism (Cd36, Hsl, Atgl) and significant upregulation of β-oxidation 
genes (Cpt1b, Acadl) (Figure 26a, b). Concomitantly, MS275 reprogrammed WAT 
toward brown-like phenotype, as genes highly expressed in brown fat (Adrb3, Cidea) were 
strongly upregulated in both WAT (Figure 26a, b). Furthermore, gene expression analysis 
of viscWAT showed dramatic increase of the expression of Ucp1 (Figure 26b). These 
findings may indicate a role of “brown-like” WAT in thermogenic process, suggesting 
that the improved thermogenic capacity of MS275-treated mice (Figure 23a) could be 
due not only to the enhanced functionality of brown fat but also to the increased oxidative 
potential of visceral WAT. 
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Figure 26: a) Gene expression analysis of functionality markers, genes involved in lipid 
catabolism, “browning” and mitochondrial biogenesis in subcutaneous WAT, b) Gene expression 
analysis of functionality markers, genes involved in lipid catabolism, “browning” and 
mitochondrial biogenesis in visceral WAT. Statistical analysis: Student’s t test, *p<0.05, **p<0.01, 
***p<0.001. 
 
 
Class I histone deacetylases regulate adipocyte precursor differentiation fate 
 
Our findings in DIO mice suggested the role of class I HDACs in the regulation of 
adipose tissue functionality. To investigate the molecular mechanism underlying the effect 
of MS275 in WAT, we performed further in vitro experiments. In both subcutaneous and 
visceral WAT there are different cell populations: among them preadipocytes and mature 
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adipocytes. The question we asked was whether MS275 exerts its effect on differentiated 
adipocytes or whether it affects adipocyte precursor cell fate. To this end we chose 
C3H10T1/2 cells, a mesenchymal stem cell line that in addition to classical hormonal 
inducers requires further stimuli (i.e. BMP4/7, Rosiglitazone) to differentiate to 
adipocytes239,240. 
Class I HDAC inhibition induces morphological changes in differentiating C3H10T1/2 
mesenchymal stem cells 
We treated C3H10T1/2 preadipocytes with vehicle or with 1µM MS275 at induction of 
the differentiation program (ind) or after differentiation (p.d.). We found that only cells 
treated with the class I HDAC inhibitor at the beginning of differentiation showed 
different morphology (smaller cells, with smaller lipid droplets) (Figure 27), while 
treatment in differentiated adipocytes had no effect. 	  
 
 
 
Figure 27: C3H10T1/2 cells differentiated in presence of MS275 were smaller after 9 days of 
differentiation (upper panel on the right).  
Class I HDAC inhibition enhances oxidative capacity in C3H10T1/2 mesenchymal stem 
cells 
Based on these morphological changes we hypothesized that MS275 treatment activated 
the oxidative program, leading to reduced lipid accumulation and consequently to smaller 
lipid droplets. In addition, we found that treatment with MS275 both at the end of 
differentiation (Figure 28a) or during differentiation program (Figure 28b) upregulated 
the expression of gene encoding dehydrogenase of long chain acyl-CoA (Acadl), a key 
enzyme of fatty acid β-oxidation and of the gene encoding isocitrate dehydrogenase 3α	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(Idh3a), an enzyme of Krebs cycle. The effect of MS275 on the expression of Acadl was 
more pronounced in cells treated with the inhibitor from the beginning of differentiation 
(3.5 fold increase). Consistently, we detected higher glycerol release in the medium of 
cells differentiated in the presence of MS275, an index of fatty acid β-oxidation, only in 
cells exposed to inhibitor from day 1 of differentiation (Figure 28c). 
 
Figure 28: a) Gene expression analysis of markers of fatty acid beta oxidation and Krebs cycle in 
cells differentiated and exposed to vehicle or to MS275 in the last 24 hours; b) Gene expression 
analysis of markers of fatty acid beta oxidation and Krebs cycle in cells differentiated in presence 
of  vehicle or MS275. Statistical analysis: Student’s t test, **p<0.01, ***p<0.001; c) Measurement 
of glycerol release in medium of differentiated cells in all the cited conditions. ND: cells not 
differentiated, DIFF: cells differentiated with classic cocktail. Statistical analysis: One way 
ANOVA, Tukey as post hoc test, ***p<0.001. 
Class I HDAC inhibition does not affect lipid accumulation in C3H10T1/2 
mesenchymal stem cells 
The observation of enhanced fatty acid β-oxidation in C3H10T1/2 cells exposed to 
MS275 from the beginning of differentiation suggested reduction of lipid accumulation in 
these cells. Surprisingly Oil Red O staining reveled that, in spite of the drastic change of 
cellular morphology, lipid accumulation in cells treated with the class I selective inhibitor 
during differentiation (Figure 29) did not differ from that of control cells. 
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Figure 29: a) Oil Red O staining in C3H10T1/2 cells differentiated in presence of vehicle or 
MS275 (top panels) or differentiated with classic cocktail and treated with vehicle or MS275 in 
the last 24 hours (bottom panels); b) Oil Red O spectrophotometric quantification.  
Class I HDAC inhibition increases adipocyte functionality marker expression in 
differentiating C3H10T1/2 mesenchymal stem cells 
To gain more insights on the effect of class I HDAC inhibition on adipocyte 
differentiation and functionality we performed gene expression analysis on C3H10T1/2 
cells terminally differentiated and treated with MS275: the class I HDAC inhibitor did 
not affect the expression of the master regulator of adipocyte functionality Pparγ and it 
decreased the expression of Acrp30 and Glut4, whose expression correlates with insulin 
sensitivity. On the other hand, MS275 increased the expression of Fabp4, a key mediator 
of intracellular transport and metabolism of fatty acids in adipose tissues. The expression 
of other important markers of adipose tissue functionality, such as the transcriptional 
factors C/EBPα, C/EBPβ, perilipin (Plin), a protein that coats lipid droplets in adipocytes, 
and the scavenger receptor Cd36 (Cd36) was not affected by MS275 treatment at the end 
of differentiation (Figure 30).	  
Conversely in C3H10T1/2 cells differentiated in the presence of MS275 we detected 
significant increase of Pparγ	  expression (both at mRNA and protein level), and its main 
targets (Acrp30, Glut4, Fabp4) and others adipocyte functionality markers (C/EBPα, Plin, 
Cd36) (Figure 31). 
A kinetic study of gene expression analysis in C3H10T1/2 cells exposed to vehicle or 
MS275 from the beginning of differentiation reveled that the class I HDAC inhibitor 
induced a significant increase of all markers from day 5 of differentiation, reaching the 
maximum effect at day 9 of differentiation (Figure 32). 
Interestingly, we detected the same kinetic gene expression profile in cells incubated with 
MS275 only for the first 72 hours of differentiation program, suggesting that early 
inhibition of class I HDACs is sufficient to “imprint” preadipocytes cell fate and commit 
them to adipocytes (Figure 33). 
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Figure 30: Gene expression analysis of adipocyte markers in C3H10T1/2 cells not differentiated 
(ND), differentiated with classic cocktail (DIFF), or differentiated with classic cocktail and 
treated with vehicle (DMSO p.d.) or MS275 (MS275 p.d.) for the last 24 hours. Statistical 
analysis: Student’s t test, *p<0.05. 
 
 
Figure 31: a) Gene expression analysis of adipocyte markers in C3H10T1/2 cells differentiated in 
presence of vehicle (DMSO ind) or MS275 (MS275 ind). Statistical analysis: Student’s t test, 
*p<0.05, **p<0.01, ***p<0.001; b) Western blot analysis showing Pparγ expression in cells 
differentiated with classic cocktail and treated with vehicle (DMSO p.d.) or MS275 (MS275 
p.d.) for the last 24 hours, and in cells differentiated in presence of vehicle (DMSO ind) or 
MS275 (MS275 ind). Student’s t test, *p<0.05, **p<0.01, ***p<0.001. 
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Figure 32: Kinetic study of gene expression of adipocyte markers in C3H10T1/2 cells exposed to 
vehicle or with MS275 from the induction to the end of the experiment (day 11). Statistical 
analysis: Student’s t test, *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 33: Kinetic study of gene expression of adipocyte markers in C3H10T1/2 cells exposed to 
vehicle or with MS275 for 72 hours at the beginning of differentiation. Statistical analysis: 
Student’s t test, *p<0.05, **p<0.01, ***p<0.001. 
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Class I HDAC inhibition promotes lipid turnover in differentiating C3H10T1/2 cells 
We next wanted to investigate whether treatment with the class I HDAC inhibitor affects 
lipid turnover. To this end, we measured the expression of typical markers of lipogenesis, 
such as the gene encoding fatty acid synthase (Fasn), and of lipolysis (e.g., hormone 
sensitive lipase Hsl and the adipose TG lipase Atgl). Interestingly, we found that only cells 
exposed to MS275 from the beginning of differentiation showed statistically significant 
increase of the expression of markers of lipogenesis and lipolysis (Figure 34), suggesting 
that early inhibition of class I HDAC in differentiation program promotes greater lipid 
turnover in this cell line. 
 
Figure 34: Gene expression analysis of lipogenesis/lipolysis markers in C3H10T1/2 cells not 
differentiated (ND), differentiated with classic cocktail (DIFF), differentiated in presence of 
vehicle (DMSO ind) or MS275 (MS275 ind), and differentiated with classic cocktail and treated 
with vehicle (DMSO p.d.) or MS275 (MS275 p.d.) for the last 24 hours. Statistical analysis: One 
way ANOVA, Tukey as post hoc test, **p<0.01, ***p<0.001. 
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Inhibition of class I histone deacetylases hampers differentiation in adipose-
committed preadipocyte 
 
Surprisingly, in a different cell model of adipocyte precursor, committed preadipocytes 
3T3-L1, treatment with MS275 at the beginning of differentiation completely blocks 
differentiation program. In cells exposed to the class I HDAC inhibitor from day 1 of 
differentiation we detected significant reduction of adipocyte marker Pparγ, Glut4, Fabp4 
and Acrp30 (Figure 35). 
 
Figure 35: Gene expression analysis of adipocyte markers in 3T3-L1 cells not differentiated 
(ND), differentiated with classic cocktail (DIFF), differentiated in presence of vehicle (DMSO 
ind) or MS275 (MS275 ind), and differentiated with classic cocktail and treated with vehicle 
(DMSO p.d.) or MS275 (MS275 p.d.) for the last 24 hours. Statistical analysis: One way 
ANOVA, Tukey as post hoc test, **p<0.01, ***p<0.001. 
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Effect of tissue specific deletion of Hdac3 on body weight 
 
Our previous studies with RNAi and ChIP analyses suggested HDAC3 as a candidate 
target for the metabolic effects of MS275 on energy metabolism in skeletal muscle and 
adipose tissue. Therefore, to investigate the role of Hdac3 in skeletal muscle and adipose 
tissue in a setting of obesity, we generated the tissue specific knock out mouse models of 
Hdac3 in skeletal muscle Hdac3 (H3smKO) and adipose tissue (H3atKO). At 8 weeks of 
age we fed male knock out mice and male littermates control mice (Floxed) with a high 
fat high sucrose (HFHS) diet. After 16 weeks on HFHS diet, H3smKO showed 
significant reduction of body weight when compared to floxed mice, while no differences 
were detected in H3atKO mice compared to control mice (Figure 36). These preliminary 
observations with tissue specific knock out mice, suggest that Hdac3 may be involved in 
the determination of body mass and pave the way to further investigations in these animal 
models to unravel the underlying mechanisms. 
 
 
Figure 36: Increase in body weight in knock out and wild type mice fed HFHS diet for 16 weeks. 
Statistical analysis: Student’s t test, *p<0.05. 
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Class I histone deacetylases enhance mitochondrial function of skeletal 
muscle and brown adipose tissue 
 
Skeletal muscle plays an important role in energy metabolism and recent studies showed 
that HDACs participate in metabolic regulation in this organ241. A study by Potthoff and 
colleagues demonstrated the involvement of different HDACs in differentiation and 
remodeling of skeletal muscle through transcriptional modulation of key genes of 
mitochondrial biogenesis and oxidative metabolism242. Accordingly, inhibition of class I 
HDACs increased oxidation of substrates in the electron transport chain in skeletal 
muscle gastrocnemius of db/db mice238. Here we demonstrated that this is the result of a 
mitochondrial re-organization: MS275 treated myotubes showed a higher density of small 
mitochondria, that are metabolically active, and characterized by strong oxidative 
potential.  
MS275 is known to inhibit both HDAC1 and HDAC3, although only HDAC3 
inhibition recapitulated the effect of class I HDAC inhibitor, as it up-regulated the 
expression of Pgc-1α and of its main targets238. In fact we have shown that the class I 
HDAC selective inhibitor in vitro and in vivo induced Pgc-1α transcription by blunting 
HDAC3 recruitment to MEF binding site in the Pgc-1α promoter, thus driving 
oxidative gene expression in skeletal muscle. HDAC3 is a crucial player also in the 
regulation of brown adipose tissue oxidative potential, as in vivo ChIP from BAT of 
db/db mice showed that MS275 reduced recruitment of this HDAC isoform to PPRE in 
Pgc-1α promoter. Accordingly, the class I HDAC inhibitor increased mitochondrial 
biogenesis and activity in isolated primary brown adipocytes, pinpointing a crucial role of 
HDAC3 in the regulation of oxidative capacity of brown fat. 
 
 
Class I HDAC inhibition as a strategy to cope diet induced obesity 
 
In the last decades the interest about the study of human obesity and its co-morbidities 
increased exponentially. Since western obesity is strictly related to a diet enriched in fat 
and carbohydrates, in this study we used a murine model of diet-induced obesity (DIO) to 
investigate the role of HDACs in the developing of this pathological condition.  
Class I HDACs emerged as important regulators of energy homeostasis: inhibition of this 
class of enzymes by MS275 reduced body weight, enhanced glucose tolerance and 
improved thermogenic capacity. Interestingly, unlike the effects described in db/db mice, 
in DIO mice inhibition of class I HDACs did not significantly affect skeletal muscle 
functionality. db/db mice are in fact profoundly compromised at the metabolic level and 
develop diabetes and insulin resistance at early stages of life. The link between diabetes 
mellitus and impaired muscle mitochondrial oxidative function has been established243 and 
it has been proposed that it might be associated to lower mitochondrial density244. 
However, in a model of diet-induced obesity, lipid infiltration and disruption of 
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mitochondrial functionality in skeletal muscle are probably some of the late stage 
complications of the pathological status. Thus is difficult to appreciate the beneficial 
effect of MS275 treatment on mitochondrial biogenesis in skeletal muscles in DIO mice. 
Since we did not detect relevant changes in skeletal muscle, we focused our attention to 
other important insulin-sensitive organs. The increased thermogenic capacity consequent 
to treatment with MS275 suggested us to investigate further the effects of class I HDAC 
inhibitor in BAT. Although BAT mass did not change, we found that BAT phenotype 
was improved in MS275 treated mice, which showed higher number of smaller 
multilocular brown adipocytes, expressing BAT markers such as Dio2 and Elovl3. 
Interestingly no significant changes were found in the expression of Ucp1 and Adrb3. The 
two proteins encoded by these genes, uncoupling protein 1 and β3 adrenergic receptor, are 
considered the key activators of the thermogenic program. A possible explanation for the 
increased thermogenic activation in response to cold in MS275 treated mice came from 
the analysis of white fat. Interestingly in both subcutaneous and visceral WAT from 
MS275 treated mice we observed upregulation of Adrb3, while a significant increase of 
Ucp1 was detected only in viscWAT. “Browning” of white adipose tissue consequent to 
inhibition of class I HDACs in DIO mice highlighted a different behavior of 
subcutaneous and visceral WAT. Accordingly, expression of WAT functionality markers, 
of genes involved in triglycerides and fatty acid catabolism and of mitochondrial 
biogenesis markers were upregulated in both types of white fat, but at a greater extent in 
viscWAT. To date, browning of WAT has been obtained by pharmacological treatment 
or by genetic manipulation54,76,245 in inguinal WAT or on epidydimal WAT. Our data, 
showing browning in visceral mesenteric WAT indicate that class I HDAC selective 
inhibition induces deep reprogramming in adipocyte differentiation pathway, resulting in 
more functional visceral adipocytes. White adipocytes of MS275 treated mice could, in 
fact, better internalize lipids, efficiently store them as triglycerides and used them as a 
metabolic fuel as a result of increased expression of β-oxidation genes (i.e. Acadl, Cpt1b). 
The finding of improved functionality of mesenteric white adipose tissue is particularly 
relevant when considering the link between the intra-abdominal fat accumulation typical 
of obesity and other related severe complications, such as cardiovascular events235. In spite 
of these considerations the MRI analysis revealed a significant reduction of adipose mass 
in subcutaneous WAT whereas in visceral WAT the trend did not reach statistical 
significance. This could depend on different features of viscWAT and subWAT: 
subcutaneous fat, which is less susceptible to inflammation246, is characterized by larger 
adipocytes than those of visceral fat. MS275 reduced the size of both subcutaneous and 
visceral adipocytes, however the effect was more pronounced in subWAT. This dramatic 
reduction of subcutaneous adipocytes hypertrophy can explain the reduced subWAT 
mass, as detected by MRI analysis. Conversely, gene expression analysis of functionality 
markers showed that MS275 is more efficient in visceral fat: visceral adipocytes are 
smaller than subcutaneous adipocytes yet more susceptible to inflammation because of 
their lower critical size. Thus, even though the reduction in adipocyte size is not as 
evident as in subWAT, the decrease of adipocyte hypertrophy is sufficient to rescue 
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adipocyte functionality, as assessed by gene expression analysis. On the contrary, 
subcutaneous adipocytes in obesity feature greater expandability that does not impair their 
functionality. Thus, the effects of MS275 on the expression of functionality markers are 
less pronounced in subWAT as compared to the effects observed in viscWAT. 
In the liver of DIO mice treated with MS275 we found reduced lipid steatosis, as assessed 
by histological analysis and by mass spectrometry analysis of total fatty acids. The 
reduction of hepatic steatosis contrasts with the accumulation of liver lipids seen in mice 
with specific deletion of HDAC3 in liver247,248. This difference may be ascribed to the 
effect of global versus local HDAC3 inhibition: in diabetic mice, systemic HDAC3 
inhibition (i.e., MS275 treatment) increases oxidative metabolism and energy expenditure 
in other tissues such as adipose tissue, thus preventing hepatic lipid buildup. 
Our in vivo results demonstrate that inhibition of class I HDACs in a model of diet-
induced obesity ameliorates obese and diabetic phenotype, as a consequence of improved 
functionality of adipose tissue, preventing the excessive lipid accumulation that would 
impair adipocyte function and lead to insulin resistance. 
 
 
Class I HDACs in cell fate determination of early adipocyte precursors 
  
The amelioration of adipose tissue functionality consequent to MS275 treatment raised 
new questions about the role of class I HDACs in WAT physiology. The elucidation of 
epigenetic pathways regulating early stages of adipocyte differentiation from precursors is 
still missing. Our results in mesenchymal stem cells C3H10T1/2 demonstrated that 
MS275 reduced cell size, as a consequence of reduction in lipid droplets size, only if 
added at the beginning of differentiation. Nevertheless, these cells maintained unaltered 
capacity to accumulate lipids. Considering that cells differentiating in the presence of 
MS275 accumulate similar amount of lipids compared to cells differentiated without 
MS275, we speculate that MS275 increased the number of differentiated cells. 
Considering that the onset of obesity correlates with adipocyte hypertrophy30, which is 
closely linked to adipose tissue inflammation, by increasing the number of differentiated 
adipocytes MS275 treatment prevented excessive lipid accumulation in the already 
differentiated adipocytes, ultimately avoiding the activation of inflammatory pathways. 
The net result was higher number of smaller but more functional adipocytes. 
Consistent with this interpretation, we observed that C3H10T1/2 cells differentiated in 
presence of MS275 showed a significant increase in the expression of markers of 
adipocyte functionality. On the contrary, in fully differentiated C3H10T1/2 cells 
treatment with the class I HDAC inhibitor MS275 did not affect the expression of 
adipocyte functionality marker, suggesting that inhibition of class I HDACs selectively in 
early precursors may influence the differentiation fate of these cells. At this regard, it is 
worth mentioning that adipocyte precursors exposed to MS275 only during the first 72 
hours of differentiation program expressed higher levels of adipose marker genes. This 
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suggests that class I HDAC inhibition at early stages of adipose differentiation is 
sufficient to imprint preadipocyte fate toward a different adipose phenotype. 
In this experimental setting we also detected increased expression of genes involved in 
lipogenesis, lipolysis and fatty acid β-oxidation in C3H10T1/2 cells differentiated in the 
presence of MS275, suggesting higher lipid turnover in cells treated with the selective 
class I HDAC inhibitor. This is relevant because it has been reported that healthy 
adipocytes are characterized by higher lipid turnover and that the balance between lipid 
storage and removal is important to preserve the functionality of adipose tissue, 
preventing severe metabolic impairment. It should be noted that high storage but low 
triglyceride removal promotes fat tissue accumulation and obesity, while reduction of both 
triglyceride storage and removal decreases lipid shunting through adipose tissue and thus 
promotes dyslipidaemia249. Interestingly we found increased expression of markers of 
oxidative metabolism also in fully differentiated C3H10T1/2 cells treated with MS275: 
this result suggests that class I HDAC inhibition in mature adipocytes induces a 
metabolic switch of these cells to a more oxidative phenotype, preventing further lipid 
accumulation in resident adipocytes. 
Overall, results obtained in C3H10T1/2 showed that treatment with the selective class I 
HDAC inhibitor remodels adipocytes features, providing an explanation to the restored 
functionality of WAT detected in MS275-treated obese mice. 
Interestingly, we found an opposite effect of MS275 in differentiating 3T3-L1 
preadipocytes, as the inhibitor completely abolished the differentiation, by reducing the 
expression of adipocyte markers. This result is consistent with Nebbioso et al.230 who 
demonstrated that treatment of 3T3-L1 cells with MS275 for 8 days during 
differentiation blocked adipogenesis. Several independent studies reported conflicting 
results regarding the role of HDACs in adipocyte differentiation. In 3T3-L1 
preadipocytes treated with the pan-HDAC inhibitors TSA, suberoylanilide hydroxamic 
acid (SAHA), or Scriptaid, differentiation and adipogenesis was inhibited250. Conversely, 
the HDAC inhibitors sodium butyrate and valproic acid increased differentiation of 3T3-
L1 cells to adipocyte. Some authors explained the different behavior of 3T3-L1 cells in 
response to HDAC inhibitors as related to the chemical identity of these compounds. 
Haberland and collaborators stated that the adipogenic effect of valproic acid and butyrate 
is due to their short chain fatty acid (SCFA) nature and not to the fact that these 
molecules are HDAC inhibitors226. We believe that the effects of MS275 observed in 
C3H10T1/2 cells can be explained considering the differences among the two cell lines 
used in our study. C3H10T1/2 cells are early adipocyte precursors; they can be 
differentiated to osteoblasts, chondrocytes, or adipocytes in response to appropriate 
signals251. 3T3-L1 cells are, instead, preadipocytes that are already committed toward the 
adipose fate. Thus, based on our results, we propose that the epigenome setting changes 
at different stages of adipose differentiation. Early perturbation of this setting induced by 
MS275 in C3H10T1/2 leads to the induction of the adipose phenotype here described. 
Conversely, the later perturbation of epigenome induced by MS275 in 3T3-L1 cells 
blocks adipocyte differentiation, as reported by other authors. 
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To further characterize the effect of MS275 in adipose cell lines, future experiments will 
focus on pathways involved in the early steps of differentiation programs (e.g., Wnt 
signaling and the Zfp423/Zfp521 pathway. These zinc finger proteins represent 
interesting targets since it has been reported that Zfp423 amplifies the effects of BMPs 
via a SMAD interaction domain inducing adipose lineage commitment. Zfp423 
expression in the developing adipocyte is repressed by the highly related factor Zfp521, 
which promotes osteogenesis and inhibits adipogenesis through interactions with Ebf1, a 
transcription factor required for early adipose commitment112,113. It has been demonstrated 
that Zfp521 expression declines during adipogenesis in C3H10T1/2 cells; this allows the 
expression of Zfp423 that activates the adipose differentiation program. Moreover knock-
down of Zfp521 results in increased H3K9 acetylation, an epigenetic mark of 
transcriptionally active chromatin, in the Zfp423 promoter region205. Thus Zfp423 could 
be a possible target of MS275 effect in the early stage of differentiation. 
Furthermore, it has been reported that Zfp521 interacts with HDAC3 and that this 
complex regulates the osteoblastic differentiation program of progenitor cells252. 
Considering that adipocytes and osteoblasts arise from the same precursor, we theorize 
that, as demonstrated for other cellular models (e.g. C2C12 myotubes and primary brown 
adipocytes) HDAC3 could be a player in the mechanism whereby MS275 regulates 
preadipocyte fate. Further chromatin immunoprecipitation experiments will be required 
to probe this hypothesis, to cast a new light upon the role of histone deacetylases in the 
regulation of adipocyte commitment. 
 
 
Deletion of Hdac3 in skeletal muscle prevents body weight gain 
 
Our latest results in skeletal muscle Hdac3 knock out (H3smKO) and adipose tissue 
Hdac3 knock out (H3atKO) fed for 16 weeks with a diet enriched in fat and 
carbohydrates (HFHS) showed that only Hdac3 deletion in skeletal muscle reduced 
weight gain significantly. These promising results confirmed the key role of skeletal 
muscle in the regulation of energy homeostasis and suggested HDAC3 as an important 
regulator of muscle metabolism and function. Furthermore, even though we observed no 
change in body weight gain during challenge with HFHS diet in H3atKO, we cannot 
rule out that Hdac3 may play a role in adipose tissue functionality. HDAC3 in fact, along 
with the transcriptional corepressor NCoR1 participates in the formation of repressive 
complex that binds Pparγ promoter205. Recently Olefsky and collaborators demonstrated 
that specific adipose deletion of NCoR1 increased obesity. Nevertheless, NCoR1 adipose 
tissue knock out (AKO) mice showed improved glucose tolerance. Euglycemic clamp 
studies demonstrated enhanced insulin sensitivity in liver, muscle and fat208. Accordingly, 
we will investigate whether adipose deletion of Hdac3 will recapitulate a phenotype 
similar to that of the AKO mice. 
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Conclusions 
 
The results reported in this thesis demonstrate the importance of class I histone 
deacetylases in the regulation of several aspects of energy metabolism. First, in depots 
enriched in mitochondria, as skeletal muscle and brown adipose tissue, the inhibition of 
class I HDACs stimulates mitochondrial biogenesis and mitochondrial function, 
potentiating the oxidative capacity of these tissues. On the other hand, inhibition of these 
enzymes reverts the loss of functionality of obese white adipose tissue, due to the 
activation of an oxidative program in differentiated adipocytes and to a reprogramming of 
adipocyte precursor fate toward a healthier adipose phenotype. Based on literature and on 
our results, our hypothesis is that these effects can be ascribed to inhibition of HDAC3. 
Further in vivo and ex vivo studies in skeletal muscle and adipose tissue Hdac3 specific 
knock out mice will be required to test this hypothesis. The full characterization of the 
phenotype of these mouse models will shed a new light on the role played by HDAC3 in 
the pathophysiology of metabolic disorders. 
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